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Abstract 
During hematopoiesis, multilineage progenitor cells and the precursors are 
committed to individual hematopoietic lineages. In normal myelopoiesis, the immature 
myeloid cells (IMCs) differentiate into macrophages, neutrophils or dendritic cells. 
However, under tumor burden, these IMCs differentiate into myeloid derived suppressor 
cells (MDSCs) result in an up-regulation of immune suppressive factors and pro-tumor 
effect. The development of normal or malignant is tightly controlled by endogenous 
signals such as transcription factors and epigenetic regulations. HDAC11 is the newest 
identified members of the histone deacetylase (HDAC) family. Previous study in our 
group had identified HDAC11 as a negative regulator of interleukin 10 (IL-10) production 
in antigen-presenting cells (APCs). However, the mechanisms of HDAC11 in regulating 
myeloid cells differentiation and function remained unclear. 
We have uncovered for the first time that in the absence of HDAC11, upon LPS 
stimulation, neutrophils isolated form mice displays an over-production of pro-
inflammatory cytokines such as TNF-alpha and IL-6. Strikingly, these HDAC11KO 
neutrophils showed a significantly higher migratory and phagocytosis activity, resulting 
from an overexpression of the migratory receptor and cytokine CXCR/L2. We have 
performed Chromatin Immunoprecipitation (ChIP) analysis on the neutrophils and 
discovered that HDAC11 was recruited to the promoter regulatory region of these genes 
we have identified. This part of data will be discussed mainly in chapter 2. 
 viii 
Not only does HDAC11 plays a crucial role in the neutrophil function, our group 
have also found out that lacking of HDAC11 result in an increased suppressive activity 
of the Myeloid-derived Suppressor Cells (MDSCs). The previous publication of our 
group had shown that the tumor bearing mice experienced a much more aggressive 
growth pattern in the HDAC11 KO mice compare with C57BL/6 wild type control. 
MDSCs isolated from mice lacking HDAC11 appeared to gain increased capability to 
suppress the function of antigen-specific CD8+ T cells in vitro. Followed by this initial 
study, in chapter 3, we observed an up-regulation of both expression and enzymatic 
activity of arginase 1 and Nos2, two enzymes that are crucial in regulating MDSCs 
suppressive function. The aberrant enzymatic activity of Arg1 and Nos2 in HDAC11KO 
MDSCs is possibly result from an over-expression of the lineage-specific transcription 
factor C/EBPβ, which is previously proved to be essential for the differentiation of 
functional MDSCs. Furthermore, our ChIP data confirmed that HDAC11 may play as an 
negative regulator of C/EBPβ. Recently, our lab had demonstrated that T cells lacking 
HDAC11 gained a hyperactive phenotype and anti-tumor effect, indicating that HDAC11 
may play a dual role in the host immune system. We further performed an adoptive 
transfer therapy to C57BL/6 tumor bearing mice. Our data showed that the additional 
administration of HDAC11KO MDSCs could eliminate, at least partially, the anti-tumor 
effect by adoptive transfer of HDAC11KO T cells. 
Taken together, we have uncovered a previously unknown role for HDAC11 as a 
transcriptional regulator in the myeloid cells differentiation and function. Based on our 
data and previous work from our lab, we propose a dual role of HDAC11 played in the 
host immune system. In the absence of HDAC11, host defenders such as neutrophils 
 ix 
and T cells are functionally more aggressive against intruders such as pathogen and 
cancer. However, the immune suppressors such as MDSCs became more suppressive. 
The contradictory role HDAC11 played in the immune system may provide some 
insights for the assessment of the pharmacological value of HDAC11 and contribute to 
the development of novel immunotherapeutic strategies. 
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Chapter 1: Background 
 
1.1 Cancer 
Cancer is the second leading cause of death in the United States and a major 
health problem worldwide.  There are 1,688,780 new estimated cancer cases and 600, 
920 estimated cancer death in the United States in 2017. Prostate, lung & bronchus and 
colon & rectum are the top three types of cancer incidence in male with estimated 
incidence rate of 19%, 14% and 9% respectively. In women, breast cancer consist 30% 
of projected cancer incidence along with other two leading cause lung and colon cancer. 
In both sex, lung cancer appears to be the top projected cause of death in 2017 [1]. 
Overall, both cancer incidence and death rate are slowly decreasing since 2004 and 5-
year survival rate has increased by 20%, possibly benefit from the development of 
treatments, introduction of cancer screening and more access to medical care among 
all population [1]. However, the efficacy of current therapeutic strategies is limited by the 
unresponsiveness and resistance from patients after treatment. The complexity of 
tumorigenesis remains a huge challenge to the development of therapeutics. 
In their paper published in 2000, Hanahan and Weinberg proposed a model for 
six features that were shared by most even all human cancers: sustained proliferative 
signaling, evasion of growth suppression, ability to metastasize, replicative immortality, 
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ability to induce angiogenesis and resistance to cell death [2]. With new knowledge 
gained by current developments in the cancer research field, this model was further re-
defined by Yousef Ahmed Fouad and Carmen Asnei with seven hallmarks by combining 
a few common features together and adding three new hallmarks: metabolic rewriting, 
an abetting microenvironment and immune modulation [3]. Interestingly, many recent 
studies provide evidences indicting that many mechanisms for tumorigenesis are 
shared among different hallmarks. Finding over-lapping areas cross cancer types can 
benefit the development of cancer therapies in a long run.  
 
1.1.1 Cancer and host immune system 
The host immune response, which has been studied extensively for the past few 
decades, can be broadly categorized as innate immunity and adaptive immunity. It is 
well accepted that the adaptive immunity relies on the innate immunity during the 
initiation and development of adaptive effector mechanisms. Upon pathogen recognition, 
cellular mediator for the innate immunity such as macrophages, neutrophils and nature 
killer cells migrate toward the location of infection and produce high level of cytokines 
and chemokines to direct the killing or phagocytosis of infected cells. The antigens 
recognized by antigen-presenting cells such as macrophages and dendritic cells will 
then be presented to the key components for adaptive immunity and direct the clonal 
expansion of antigen-specific effector cells selected by receptor gene rearrangement [4, 
5].  
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In both cancer patients and tumor bearing animal models, it is widely observed 
the host immune system often silenced when encounter tumors. The theory of cancer 
immune surveillance was accepted with the observation of the defensive machinery in 
the host body that was associated with immune mediated rejection of tumors in mouse 
models. However, despite the immune surveillance tumor maintained its capability of 
continuous development. The phenomenon of cancer immunoediting, which includes 
three stages as elimination, equilibrium and escape, can best summarize the interaction 
between tumor and host immune system. The elimination phase can best describe the 
process of host immune response against cancer: by recognition of tumor cells, the 
innate immune cell undergoing maturation and migration followed by the presentation of 
tumor antigen and priming of cytotoxic T lymphocytes, which triggers the homing of 
these T cells to tumor site and directs the killing of tumor cells. The continuous 
elimination of tumor cells can then trigger the tumor cells evolution by the selection of 
cells with reduced immunogenicity and increased resistance. This process defines the 
second phase: equilibrium. The final step of tumor immunoediting is involved with the 
evasion of immune surveillance and elimination and eventually results in tumor 
"escape" (reviewed in [6]).    
During the phase of selection, tumor cells are undergoing multiple genetic and 
epigenetic alterations toward a "suitable" phenotype that could potentially survive the 
immune attack. Mechanisms generated by tumor cells include 1) reduced antigen 
recognition by alter either tumor cell surface marker expression or the effector T cells, 2) 
induce immunological ignorance and tolerance through tumor secreted 
immunosuppressive factors or recruitment of immunosuppressive cells such as myeloid-
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derived suppressor cells and tumor associated macrophages, 3) reduce 
cytokine/chemokine mediated cell death [3].  
In order to evade the immune surveillance and promote its progression, tumor 
cells generate multiple mechanisms to "build" or "re-edit" the local microenvironment 
they were growing in. The tumor microenvironment provides physical support, nutrition 
and chemical signals for the tumor growth. However, large amount of immune cells and 
non-immune cells are recruited to the TMEs as well. Large amount of literatures had 
reported the infiltration of T cells, myeloid cells and cancer-associated fibroblasts in the 
microenvironment. The crosstalk between these cells and tumor cells can significantly 
impact the effectiveness of cancer therapy. The infiltration of antigen-specific effector T 
cells in the TMEs could potentially provide immune defense against cancer and present 
as a good prognostic marker. However, the anti-tumor function of those T cells is often 
suppressed by either tumor cells or other immunosuppressive cells recruited by the 
tumor. The reprogramming of immunosuppressive factors in the TMEs will be discussed 
later in this chapter.  
 
1.1.2 Hematopoiesis and abnormal myelopoiesis 
Hematopoiesis plays a crucial role in the immune system in humans. The 
hematopoietic stem cells (HSCs) are responsible for the production of all lineages of 
blood cells at a daily basis. Upon stimulation with different kind of signals such as 
growth factor and cytokines, HSCs undergoes multiple steps of differentiation and 
commitment and eventually give rise to multiple lineages of cells. In the bone marrow, 
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common myeloid progenitor cells (CMPs) will be further differentiated into 
Megakaryoblast, Proerythroblast, master cells and Myeloblasts, whereas common 
lymphoied progenitor cells (CLPs) will be further differentiated into B, T lymphocytes 
and lymphoid dendritic cells. The Myeloblasts will eventually give rise to 
monocytes/macrophages, neutrophils, dendritic cells, basophils and eosinophils. At 
steady state, hematopoiesis is strictly regulated by different genetic and epigenetic 
modulations to maintain homeostasis of the host immune system. However, under 
pathological conditions such as infection, HSCs will undergoing expansion and induce 
the production of different kinds of blood cells to replace the cells that are "consumed" 
during innate and adaptive immune responses.   
During tumorigenesis, abnormal myelopoiesis could occur in response to a 
persistent signal of growth factors (such as GM-CSF, G-CSF and M-CSF) produced by 
tumor cells or tumor induced inflammation [7]. As a result, large amount of immature 
myeloid cells will enter the blood stream and migrate to the sites of demand.  As 
previously discussed, tumor cells can develop multiple mechanisms to evade immune 
surveillance such as induced immunosuppressive pathways. During this tumor induced 
emergency myelopoiesis, once being released to the blood, the immature myeloid cells 
will differentiated into functional suppressive MDSCs and enter the tumor 
microenvironment [8-10]. Moreover, besides growth factors listed above, cytokines such 
as IL-1β can also induce increased hematopoiesis in the bone marrow in tumor bearing 
mice, possibly through the release of increased level of serum IMCs induced by IL-1β 
[11]. Interestingly, recent studies had demonstrated that tumor induced abnormal 
myelopoiesis can be mediated by HDAC inhibition. Besides the direct cytotoxic effect of 
 6 
HDAC inhibitors on cancer cells, HDACi has been shown to induce the cytotoxic activity 
of CD8+ T cells against cancer. However, administration of HDACi in vitro result in an 
enhanced bone marrow proliferation and functional MDSCs expansion [12]. To date, the 
mechanism of HDAC inhibition affect myelopoiesis is not fully understood yet. In chapter 
two and three of this dissertation, questions regarding to mechanistic role of HDAC11, 
the newest member of the HDAC family, in hematopoiesis under pathological conditions 
such as infection and cancer will be further addressed. 
 
1.1.3 Current approaches for cancer immunotherapy 
Currently many different types of immunotherapy are used to treat cancer. (1) 
The monoclonal antibodies. Some mABs are designed to bind to specific surface 
receptors and function as an agonist or antagonist, which can potentially cause an 
immune response that eliminates cancer cells. Other types of mABs may bind to the 
surface of cancer cells and direct immune recognition or the delivery of a cytotoxic 
agent [13]. (2) Cytokine treatment. The infusion of cytokines such as interferons and 
interleukins could potentially induce the proliferation and responses of the immune cells. 
However, it also proved to be associated with various side effects and limited clinical 
outcomes. (3) Adoptive cell transfer. T cells isolated from the tumor have the potential to 
recognize tumor cells and are actively against them. Ex vivo expansion of those tumor-
specific T cells and re-introduce to the patients can restore the anti-tumor immune 
response in many cases. The T cells from patients can also be genetically modified 
before re-infuse into the patients. More recently, CAR-T cell therapy has been approved 
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by the Food and Drug Administration (FDA) in treatment of ALL. (4) Vaccine treatment. 
Cancer vaccines such as polypeptide based, whole cell, or viral vector can work against 
cancer by induce the responses by host immune system.  
One challenge for modern cancer immunotherapy such as adoptive T cell 
transfer is to overcome the immunosuppressive microenvironment modulated by tumors. 
The suppressive feather of the TMEs is associated with multiple factors such as cancer 
types and disease stages, as the host immune system is possibly compromised with 
advanced disease. Targeting the suppressive cells/factors in the TMEs or giving the 
treatment at an earlier stage might provide a better outcome in combination with these 
therapies.  
 
1.2 Tumor microenvironment 
Cancer cells are the crucial components to form a malignant tumor. But the 
malignant phenotype of cancer cells cannot be achieved without the surrounding cells in 
the local environment where primary or metastasis tumor mass was formed. Together 
with tumor cells, the non-malignant cells such as lymphocytes, myeloid cells, fibroblasts, 
along with the extracellular matrix, blood vessels and other supporting structures 
composed tumor microenvironment [14]. The infiltrated non-malignant cells in the tumor 
microenvironment displayed a dynamic and tumor promoting function during the 
initiation, progression and metastasis of many solid tumors [15]. Both tumor cells 
themselves and infiltrated immune cells can release a wide range of different cytokines, 
chemokines and growth factors which can contribute to the tumorigenesis, recruitment 
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of immune cells, as well as suppression of T cell function. The cross talk in between 
tumor cells and infiltrated cellular and non-cellular components in the microenvironment 
formed a dynamic network and brought huge challenge for therapeutic targeting the 
tumor microenvironment. 
 
1.2.1 Tumor infiltrated T lymphocytes 
Studies had documented evidence of many different T lymphocyte populations 
infiltration in tumors and the draining lymphoid organs. The prognostic significance of 
those tumor infiltrated T cells is in debate considering the functional diversity of this 
heterogeneous population of T cells when interacting with tumor cells or other cellular 
components in the tumor microenvironment. 
Higher number of infiltration of cytotoxic CD8+ memory T cell which have the 
capability to recognize antigen and kill tumor cells are generally correlate with good 
prognostic [16]. CD4+ T helper 1 cells (Th1, produce IL-2 and IFN-γ), which support 
CD8+ T cell function, are also considered as good prognostic when largely infiltrated in 
the tumors [16]. On the contrary, CD4+ T helper 2 cells (Th2, produce cytokine such as 
IL-4, IL-13 and IL-5)) and immnosuppressive regulatory T cells (Tregs express surface 
marker Foxp3 and CD25) in the tumor microenvironment are believed to be tumor 
promoting [16, 17]. Additionally, higher number of Tregs in the blood of diffuse large B-
cell lymphoma is associated with poor prognostic, but Tregs can be tumor suppressive 
in Hodgkin's lymphoma patients [18-20]. 
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However, multiple mechanisms had been identified to discharge Cytotoxic T 
cell's anti-tumor function in the microenvironment. The key effectors that contribute to 
the immune dysfunction include tumor cells, suppressive immune cells and stromal 
cells. Tumor cells often over-express or down-regulate certain cytokines to manipulate 
immune responses. For instance, over-expression of CCL2 in colorectal cancer result in 
increased recruitment of tumor associated macrophages that contribute to cancer 
progression [21]. Enhanced secretion of chemokine ligand CCL22 by breast cancer is 
associated with the infiltration of regulatory T cells [22, 23]. Lacking expression of 
CCL2, CCL3 CXCL5, CXCL10 in metastatic melanoma can forbid antigen-specific T cell 
infiltration [23, 24]. Besides chemokines, tumor cells can up-regulate checkpoint 
proteins such as cytotoxic T lymphocyte antigen-4 (CTLA-4) and programed cell death-
1 (PD-1) on tumor infiltrated T cells, which are originally part of the normal suppressive 
mechanism during immune response, result in down-regulation of those T cell response 
and exhaustion [25].  
 
1.2.2 Myeloid-derived suppressor cells 
Myeloid-derived suppressor cells are defined as a heterogeneous population of 
inhibitory immune cells that are expanded result from abnormal myelopoiesis and 
neutrophilia in various cancers in murine models and humans [26]. MDSCs were first 
observed in the 1980s and were called "nature suppressor cells" characterized with its 
inhibitory ability to T cell proliferation and cytotoxic T cell generation. They were soon 
discovered in multiple cancer types such as head and neck, as well as murine animal 
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model bearing spontaneous and transplanted tumors [27, 28]. Researchers had 
struggled how to term this special population of cells and until 2007 the terminology of 
"myeloid-derived suppressor cells (MDSCs)" was finally accepted [29].    
 
1.2.2.1 The origin of MDSCs 
Based on currently knowledge, MDSCs are believed to originate from the bone 
marrow in both human and mouse (a small amount of MDSCs are believed to originate 
from spleen in mouse). They are derived from the hematopoietic stem cells to the 
common myeloid progenitor and the granulocyte/macrophage progenitor cells. During 
steady state hematopoiesis, these GMP cells usually further commit to granulocytes 
and macrophages. However, under pathological conditions such as cancer progression 
(sometimes infection), the GMPs will further differentiated into MDSCs in bone marrow, 
blood, lymph nodes, spleen, tumor site and metastasis, with an expansion of more than 
20% of total cells [30]. Originally, MDSCs are defined as cell express surface marker 
CD11b and Gr-1 (Ly6G/Ly6C). However, during normal hematopoiesis, CD11b+Gr-1+ 
cells constitute 20 to 30% of total cells in the bone marrow and 2 to 3% in the spleen. 
The surface markers are not exclusively expressed on MDSCs, which make it 
necessary to include the functional characterization as part of the strategy to identify 
this special population.  
 
 
 11 
1.2.2.2 MDSCs expansion 
Several growth factors were demonstrated to affect the MDSC expansion: 
granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte colony-
stimulating factor (G-CSF) and macrophage colony-stimulating factor (M-CSF). During 
myelopoiesis at steady state, GM-CSF, G-CSF and M-CSF are believed to play a 
crucial role in the maturation, proliferation, recruitment and survival of granulocytes and 
monocytes. When treated with GM-CSF and/or G-CSF in vitro, bone marrow precursor 
cells acquired a similar surface phenotype and function to MDSCs induced by cancer 
[31, 32]. Thus, it is not surprising that the high secretion of GM-CSF and G-CSF from 
cancer cells is associated with MDSCs expansion and infiltration. Long-term exposure 
of high level of GM-CSF and G-CSF produced by cancer cells affect the generation, 
maintenance and survival of MDSCs in cancer patients [33]. However, there's no 
evidence showing that short administration of GM-CSF to patients has the same effect 
[34]. 
 
1.2.2.3 Subsets of MDSCs 
Recently, two major subsets of MDSCs have been identified based on their 
morphology and surface markers expression: monocytic MDSC (M-MDSC) and 
granulocytic MDSC (G-MDSC, also called polymorphonuclear PMN-MDSC) [35, 36]. In 
mice, M-MDSCs are characterized as CD11b+Ly6G-Ly6Chigh while G-MDSCs as 
CD11b+Ly6G+Ly6Clow [36-38]. However, in cancer patients, the definition of phenotype 
of human MDSCs is unclear. By far human M-MDSCs are defined as 
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CD11b+CD14+CD33+HLA-DR-/lowCo-receptor-/low and G-MDSCs as 
CD11b+CD15+CD33+Lin-HLA-DR-/low expressing cells [8, 39].  
Functionally, M-MDSCs are believed to be highly immunosuppressive in both 
antigen specific and non-specific manner, whereas G-MDSCs' immunosuppressive 
effect is moderate and its promotion to T cell tolerance is antigen-specific. Monocytic 
MDSCs express high level of both immunosuppressive enzymes arginase and inducible 
oxide synthetase (iNOS), but could not produce high level of reactive oxygen species 
(ROS). On the contrary, granulocytic MDSCs are capable of the expression of high level 
of arginase and the production of high level of ROS, but fail to express iNOS [26, 40]. 
Besides increased expression of Gr-1 surface marker on both populations, M-MDSCs 
express high level of IL-4 receptor alpha (IL-4α) compare with G-MDSCs [41]. However, 
the low intensity of IL-4α on and its inconsistent expression pattern on in different 
cancer hosts forbid it to become a good surface marker to distinguish the subsets of 
MDSCs [42, 43].  
 
1.2.2.4 Mechanisms regulating MDSCs biology 
Two major questions regarding MDSCs biology are: 1), what is the mechanism(s) 
that regulates MDSC generation and expansion; 2), what controls their tumor promoting 
function. Recent studies had established multiple signal pathways that were regulating 
MDSC expansion and function. The transcription factors involved with those pathways 
often overlap or have impact on each other and formed a complicated signal network 
that benefit MDSCs suppressive capability.  
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The signal transducer and activator of transcription (STAT) family had been 
demonstrated to play an important role in different mechanisms. Activation of STAT3 
can directly promote proliferation; prevent cell apoptosis and differentiation in MDSCs, 
through over-expression of Bcl-xL, c-myc and cyclin D1 [30]. Another pathway STAT3 
involved with is the calcium-binding pro-inflammatory protein S100A8 and S100A9 [44]. 
Upregulation of S100A8 and S100A9 by STAT3 result in MDSCs accumulation in mice 
[9, 44]. Activation of STAT3 was also proven to directly relate with up-regulation of ROS 
production in MDSCs, possibly through up-regulation of the NADPH oxidase (Nox2) 
components P47phox and gp91phox [9]. Notable, there's new evidence showing that 
STAT3 activation result in an up-regulation of transcription factor CCAAT-enhancer-
binding protein beta (C/EBPβ), in responding to G-CSF in vitro [31]. C/EBPβ plays a 
crucial role in the differentiation and immunosuppressive function of BM-derived and 
tumor-induced MDSCs. Mice lacking C/EBP-β in the bone marrow compartment 
appeared to lose the ability to differentiate from IMCs into pathologically active MDSCs, 
possibly through a reduction of arginase 1 and Nos2 proteins expression [31]. In 
addition to STAT3, other members of the STAT family had shown to be associated with 
MDSCs function. In response to IL-1β or IFN-γ, STAT1 can up-regulate iNOS and 
arginase activity, leading to a functionally more suppressive MDSCs phenotype [45, 46]. 
Some studies reviewed that STAT5 and STAT6 played a crucial role to MDSC survival 
and function through multiple pathways.  
One mechanism of the suppressive function in MDSCs is mediated by Arginine 
metabolism. Arginine is a non-essential amino acid for adult human and its metabolism 
is largely associated with immune response. L-Arginine deprivation has no effect on 
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primary T cells at steady state, from both mouse and human. Once activated in L-
Arginine free culture medium, T cells appeared to have decreased expression of CD3ζ 
chain and down-regulation of NFκB-p65 and Jak-3, as well as a reduced proliferation 
and inability of IFN-γ production [47, 48]. Arginine can be metabolized by a few 
enzymes such as arginase, nitric oxide synthase (NOS), arginine:glycine 
amidinotransferase (AGAT) and arginine decarboxylase. In MDSCs, higher expression 
of Arg1 and Nos2 are often detected among different subsets that are related with 
MDSCs to T cell suppression. There are two isoforms of arginase, Arg1 and Arg2. 
Arginase 1 mainly expresses in myeloid cells and hepatocytes. Arginase 2 can be found 
in tissues such as kidney, brain and small intestine [48]. Arg1 can convert L-arginine to 
urea and L-ornithine, whereas Nos2 can generate nitrite oxide (NO) and L-citrulline 
when utilize L-arginine. Increased NO production by MDSCs infiltrated into tumors is 
associated with T cell suppression through interfering T cell and APC communication, 
inhibit T cell signaling downstream of IL-2R and induce T cell apoptosis [49-51]. Up-
regulation of Arg1 and Nos2 in MDSCs are mediated through different signal pathways. 
Activation of STAT6 and up-regulation of transcription factor C/EBPβ and STAT3 are 
associated with increased Arg1 expression in MDSCs. Additionally, multiple cytokines 
and growth factors such as IL-4, IL-10, IL-13, TGF-β and GM-CSF can induce the 
expression of Arg1 as well [48]. Moreover, Nos2 production can be induced in response 
to IFN-γ, TNF-α and IL-1β as mentioned before.   
In addition to up-regulation of Arg1 and Nos2, increased expression of NOX2, the 
catalytic subunit of NADPH oxidase can result in increased level of ROS in granulocytic 
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MDSCs, mediating T cell inhibition through downregulating CD3ζ chain expression, 
reducing cytokine production and impairment of the differentiation of MDSCs [52]. 
Besides directly suppress T cell function, MDSCs was found to induce the 
development of CD4+CD25+Foxp3+ Tregs in a colon carcinoma mouse model [53]. 
Additionally, a few inhibitory methods that are used to reduce MDSCs function were 
found to contribute to reduce Treg function and expansion [54, 55].  
 
1.2.2.5 Clinical evaluations of MDSCs 
The important role of MDSCs has been acknowledged for tumor initiation, 
progression and immune evasion. However, in clinic, the expansion of MDSCs has 
been correlated with advanced stages in multiple cancer types such as head and neck 
squamous cell carcinoma, none small cell lung cancer (NSCLC), hepatocellular 
carcinoma (HCC), bladder cancer, pancreatic cancer and hematological malignancies 
such as non-Hodgkin lymphoma (reviewed in [56]). Moreover, besides tumor 
progression stages, MDSCs level also correlates with patient response to therapy and 
surgery. Clinical data reviewed that circulating MDSCs level in the blood could serve as 
a predictive and prognosis marker. An example is in stage IV breast or colorectal cancer 
patients, high circulating MDSCs number is associated with poor prognosis (reviewed in 
[56]). Higher number of blood circulating MDSCs at baseline prior to chemotherapy also 
correlated with a shorter overall survival (reviewed in [56]).  
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1.2.2.6 Targeting MDSCs in cancer 
The functional characterization and clinical correlation study reviewed MDSCs as 
an important factor in cancer in general and reflect them as a potential target for 
therapeutic approaches.  The fact that MDSC is primarily correlate with T cell 
suppression indicate the potential to directly target this population or as adjuvant with 
current immunotherapy. As reviewed by many researchers, blocking MDSCs 
generation, recruitment or suppressive function, as well as converting MDSCs to APCs 
could be beneficial as potential therapeutics. One in vivo study using nitroaspirin (NCX-
4016) had observed restoration of T cell responsiveness and enhanced efficacy of 
cancer vaccination, possibly through inhibition of Arg1 and iNos activity [57]. 
Administration of all-trans retinoic acid (ATRA) or vitamin D3 result in differentiation of 
MDSCs toward matured myeloid cells thus improve the efficacy of anti-tumor 
vaccination [58]. Some earlier generations of chemotherapeutic agents such as 5-
Fluorouracyl showed to affect monocytic MDSCs apoptosis in animal models [59, 60]. 
Inhibition of CSF1/CSF1R by using CSF1R antagonist and anti-CSF1R mAB (RG7155) 
affects monocytic MDSCs differentiation and recruitment in some clinical trials [61].  
Although increasing therapeutics have been designed to target MDSCs through 
different pathways, more investigation should be dedicated to assess the safety, 
effectiveness and side effects of the new agents before entering clinical trial. Moreover, 
the complexity of the signal pathways regulating MDSCs function brings huge challenge 
to targeted therapeutics. A better understanding of the network mediating MDSCs 
biology will likely to benefit cancer treatment in a long run.  
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1.2.3 Tumor associate macrophages 
Tumor associate macrophages (TAMs) are a major leukocyte population 
infiltrated in tumors. Depend on the microenvironment; macrophages could acquire 
different phenotypes associated with different functions. Classically activated 
macrophages (M1 macrophages) and alternatively activated macrophages (M2 
macrophages) are often considered to be the two major polarized phenotypes of 
macrophages. M1/M2 macrophages are driven from different cytokines. IFN-γ or LPS 
can induce M1 macrophages that are generally considered to be pro-inflammatory. M2 
macrophages can be polarized in response to IL-4 and IL-13 and are characterized with 
anti-inflammatory phenotype. Tumor associated macrophages are usually linked with 
M2 macrophages. However, the transcription profile of TAMs is quite distinct from both 
phenotypes [62, 63].  
Unlike regular macrophages, which have the potential to eliminate tumor cells, 
tumor associate macrophages are one of the major contributors to many stages of 
tumor progression. The pro-tumorigenic effect of TAMs is largely reflected on their 
involvement with tumor cell migration, invasion and metastases. The 
immunosuppressive effects of TAMs and MDSCs are overlapping in many manners. For 
instance, both TAMs and MDSCs can suppress T cell function in an antigen-specific 
and non-specific manner. TAMs and MDSCs can both induce CD4+CD25+Tregs 
generation and recruitment [64, 65]. Similar to MDSCs, TAMs shared high enzymatic 
activity for L-arginine consumption that deploys one of the most powerful suppressive 
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features in regulating T cell response and proliferation [66]. In addition to immune 
suppression, TAMs and MDSCs both played a crucial role in promoting tumor 
angiogenesis by secreting VEGF, CXCL8/IL-8 in response to hypoxia [56].  
 
1.2.4 Other cellular and non-cellular components in the tumor 
microenvironment 
Besides T lymphocytes and suppressive myeloid cells, other types of immune 
cells can be found at the invasive margin of some tumors and/or draining lymph nodes 
as well. The infiltration of natural killer cells (NK cells) and natural killer T cells (NKT 
cells) can be found in some cancer types and are associated with a good prognosis 
[67]. Dendritic cells (DCs) and tumor associated neutrophils (TANs) are also reported to 
infiltrate tumors. However, the primary function of DCs and TANs that are related with 
antigen processing and presenting are usually defective. Instead, when interact with 
malignant cells or local microenvironment, they appear to promote tumor progression by 
suppressing T cell response or enhancing tumor growth and angiogenesis. In addition, 
the infiltration of B cells in medullary ductal breast cancer and high-grade serous 
ovarian cancer was associated with good prognosis [68, 69]. However, their function 
can be switched to tumor promotion by inhibit tumor specific cytotoxic T cell response 
[70]. 
Other cellular or non-cellular components in the tumor microenvironment had 
been shown to play crucial roles in cancer progression. Myofibroblasts in TME, also 
known as cancer-associated fibroblasts (CAFs), are associated with promotion of 
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cancer cells growth and survival, maintaining the immune suppressive 
microenvironment as well as inducing epithelial-mesenchymal transition (EMT) through 
secretion of growth factors and chemokines [71]. Adipose cells and tissue are 
associated with secretion of large amount of cytokine, chemokine and hormone-like 
factors to support and maintain a pro-inflammatory microenvironment, contributing to 
tumor progression and immunosuppression. In addition, the non-cellular components in 
TMEs, extracellular matrix (ECM), contain cytokines and growth factors secreted by 
tumor cells and stromal, which contribute to tumor growth and recruitment of 
immunosuppressive cells [71]. ECM also provides a physical scaffold for all cells in the 
tumor microenvironment, helping maintain tumor homeostasis.  
 
1.2.5 Strategies of targeting the tumor microenvironment 
The cellular and non-cellular components of the tumor microenvironment permit 
and promote tumor progression in many different aspects and a lot of them were found 
over-lapping during the cross talk between each other. Therapeutic strategies can be 
developed to target both cellular and non-cellular components in the TMEs. 
(1) Targeting immune cells. Chronic inflammation induced by tumor infiltrated 
macrophages, neutrophils and master cells is usually associated with cancer 
progression. Depend on the polarization phenotype, immune cells can exert 
either anti- or pro-tumor effect. The presence of M1 macrophages, N1 
neutrophils, Th1 CD4+ helper T cells and cytotoxic CD8+ T cells sometimes 
indicate a good prognostic or favorable to immune therapy. However, these 
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immune cells possess potential anti-tumor effect that is often found to be 
suppressed through different pathways. On the other hand, cells with 
immunosuppressive phenotype such as tumor associated macrophages, 
MDSCs and regulatory T cells either promote tumor progression directly or 
suppress immune response. Thus, targeted therapeutics could be considered 
based on the unique function of a particular cell type. For instance, blocking the 
recruitment or reprograming suppressive cells in the TMEs may potentially 
reduce the pro-tumor effect and induce immune response against tumor cells. 
The cytotoxic CD8+ T cells present in the tumor is often not sufficient enough 
against tumor cells. Additional adoptive transfer of antigen-specific CD8+ T cells 
was proved to have positive effects on some patients. However, the over-all 
suppressive microenvironment those T cells encountered may potentially affect 
the anti-tumor response. Adding a suppressor cell blockade may potential 
benefit the effect for the adoptive transfer therapy. Anti-inflammatory drug have 
been found to reduce tumor incidence and could potential serve as an anti-
tumor agent, however, its side effects and specificity remains questionable.  
(2) Targeting none-immune cells in the TMEs. Cancer associated fibroblasts 
(CAFs) are involved with tumor progression and metastasis by providing 
support to tumor cell growth and cell-cell interaction in TMEs, induce 
angiogenesis and the presence of CAFs usually associated with poor prognosis 
in many cancers. Extensive cross talk between tumor cells, CAFs and immune 
cells in the TMEs was observed among different cancers, indicating that CAFs 
possessed a therapeutic value. Although a few clinical studies had failed to 
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either achieve clinical benefits or end up reducing survival rate, further 
understanding will contribute to the development of targeted therapy against 
CAFs.  
(3) Targeting non-cellular component in the TMEs. The extracellular matrix in 
TMEs facilitates support for the interaction between cancer cells and host cells. 
In addition to the physical network, ECM creates an environment contains 
different chemical signal with the ability to regulate the oxygen level, pH value 
and interstitial pressure for the TMEs [72] that affects tumor progression, which 
may provide multiple potential targets for cancer therapy. 
(4) Targeting angiogenesis. Extensive interests and developments on tumor 
angiogenesis during the past 40 years contribute to the development of 
therapeutics targeting this specific hallmark of cancer. Many clinical trials have 
been conducted using different kind of agents such as anti-VEGF antibody and 
antiangiogenetic tyrosine kinase inhibitors. However, the feedback of 
antiangiogenetic drugs turned to be modest with a lower responding rate [73], 
possibly through tumor dependent or independent resistance. Alternative 
strategies proposed by cancer researchers are using antiangiogenic drugs as 
adjuvant therapies in combination with other therapies such as chemotherapy, 
conduct trials for patients at early stage of tumor development and developing 
therapeutics against VEGF-independent angiogenic factors (reviewed in [72])  
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1.3 Histone deacetylases 
In eukaryotes, DNA is tightly compacted with an octamer of four histones (2 
H2A/H2B dimers and a H3/H4 tetramer) to form the nucleosome, subunit of chromatin. 
This highly dynamic protein-DNA complex prevents the accessibility of transcription 
factors in resting cells whereas made available through chromatin remodeling during 
post-transcriptional regulation. Epigenetic modification, including DNA methylation, 
phosphorylation, ubiquination and acetylation, could alter the chromatin architecture 
thus influence the transcriptional regulation. Although DNA methylation is well studied, 
acetylation of histones had gained increasing amount of interest for scientific 
investigators in recent years. 
Two groups of enzymes have been recognized to modify histone acetylation 
status based on their function. Histone acetyltransferase (HATs), function as epigenetic 
writers, transfer acetyl group to lysine residues on histones (and other acetyl-lysine 
containing proteins) and allow accessibility of transcription machinery to a “relaxed” 
chromatin structure and up-regulate a particular gene expression. On the contrary, the 
epigenetic eraser histone deacetylases (HDACs) remove acetyl group from histone 
tails, form a condensed chromatin and make it unfavorable to DNA binding proteins and 
repress transcription [74, 75]. 
 
1.3.1 Classification of HDACs 
Presently in humans, there are eighteen known HDACs so far with differences in 
amino acid sequence, enzymatic domain structure and tissue specific expression 
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pattern. Besides the nicotinamide-adenine-dinucleotide (NAD+)-dependent sirtuins, 
eleven out of these eighteen zin-dependent HDACs were found with conserved 
deacetylase domain and divided into four classes: class I HDACs (including HDAC1, 
HDAC2, HDAC3 and HDAC8); class II (HDACs 4, 5, 6, 7 and 9) and class IV with a sole 
member HDAC11. Class II HDACs were further divided into two sub-classes: class IIa 
includes HDAC 4, 5, 7 and 9; class IIb includes HDAC6 and HDAC10 which both have 
two catylytic sites. Class I, IIa, IIb and IV HDACs are grouped as classical HDACs [76, 
77]. 
The predominant localization of almost all HDACs was found to be the nuclear 
through a nuclear localization signal (NSL) or the co-localization with other proteins. 
Class I HDACs are mostly found exclusively in the nucleus except for HDAC3, which 
contains both a nuclear import and export signal. HDAC11 is primarily located in the 
nucleus, however, using co-immunoprecipitation, both endogenous and over-expressed 
HDAC11 can be detected in the cytoplasm when associated with HDAC6 [78, 79]. Class 
II HDACs can shuttle in and out of the nucleus, either induced by certain signal or 
depend on the splice variants [76].  
 
1.3.2 HDAC11 
Histone deacetylase 11 was first cloned and identified in 2002 by Gao and 
colleagues. The molecular weight of HDAC11 is 39 kDa with a total sequence of 347 
amino acid consisting nine exons and eight introns [79]. In humans, HDAC11 protein is 
encoded on chromatin 3p25.2 whereas on chromatin 6 in mouse [79]. As the smallest 
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member in the HDAC family, HDAC11 contains all blocks of conservative sequence in 
its catalytic domain that are identified to be important for the enzymatic activity for 
deacetylase function among other HDACs [79]. Phylogenetic analysis had reviewed 
HDAC11 is more closely related to class I HDACs and the prokaryotic AcuC protein 
than class II HDACs [79]. However, HDAC11 shared an extremely low similarity of its 
structure to class I, II and III HDACs and was granted with its own class, class IV [79].     
The expression of HDAC11 characterized in various tissues and cancer cell 
lines. Northern blotting and mRNA analysis from Gao, et al reviewed that HDAC11 
expression was highly tissue specific, with a higher expressing signature in brain, heart, 
skeletal muscle, kidney and testis, suggesting that its function may be tissue specific 
[79]. Higher level of HDAC11 was also detected in several human malignant cell lines 
such as rhabdomyosarcoma muscle tumor cell line [79]. An in vitro deacetylase activity 
assay using FLAG-HDAC11 showed that HDAC11 possessed catalytic activity shared 
by other family members, but in a much lower manner [79]. However, using a synthetic 
peptide in vitro to measure the activity might not reflect the true deacetylase ability of 
endogenous HDAC11.  
Using same FLAG-HDAC11 over-expression model, Gao's group identified a 
physical association between HDAC6 and HDAC11 293 cells [79]. Both calss I and II 
HDACs had been previously proved to function in protein complexes including 
transcription repressors and other proteins from the HDAC family. However, besides 
HDAC6, no evidence indicates that HDAC11 is physically involved with other HDAC 
family members. HDAC11 was previously found to localize in the nucleus. However, 
recent study detected the interaction of HDAC6 and HDAC11 in both cytoplasmic and 
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nuclear compartment in murine and human macrophage or promonocytic cell lines, 
through the N-terminal domain of HDAC11 and C-terminal domain of HDAC6 [78].   
 
1.3.2.1 HDAC11 in APCs 
The functional role of HDAC11 in immune cells was largely undefined until 
Villagra in our group first found out that this molecule played as a transcription repressor 
of IL-10 expression in macrophages. In response to LPS, macrophages with HDAC11 
over-expression result in decreased IL-10 expression, possibly through alteration of the 
phosphorylation of histone H3 in the proximal region of IL-10 promoter [80]. Further 
investigation by the authors showed that HDAC6 and HDAC11 played opposing roles in 
regulating IL-10 expression in APCs. The authors had demonstrated that over-
expression of HDAC6 results in an increased IL-10 production in macrophages [78]. 
Interestingly, the physical interacted HDACs were found to be recruited to the same 
region in the IL-10 promoter, suggesting the opposite role of HDAC6 and HDAC11 
played in regulation IL-10 expression might related with their dynamic interaction under 
stimulation [78].  
Recently, another group had demonstrated that HDAC11 up-regulation result in a 
down-regulation of IL-10 in Kupffer cells isolated from alcohol-fed mice, possibly 
through alcohol metabolites (ALDH) and NF-κB pathways [81]. Furthermore, decreased 
IL-10 production was observed in dendritic cells when HDAC11 was knocked down 
using shRNA. 
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1.3.2.2 HDAC11 in T lymphocytes 
The functional role of HDAC11 in T lymphocytes was characterized by two recent 
publications. Woods and Woan from our group had previously observed an increased 
effector function by T cells lacking HDAC11. Using a HDAC11 knockout mouse model, 
the authors found that in the absence of HDAC11, CD8+ T cells displayed increased 
proliferation rate and surface expression of effector molecules such as granzyme B and 
perforin [82]. Both HDAC11KO CD4+ and CD8+ T cells produced higher level of 
proinflammatory cytokines in both antigen dependent and independent manner. In 
addition, HDAC11KO T cells were less susceptible to tolerance induction and 
experience less suppression from Tregs [82]. Furthermore, in vivo study demonstrated 
an enhanced anti-tumor effect of T cells lacking HDAC11 through adoptive transfer 
therapy [82]. One proposed mechanism by the authors was HDAC11 mediate the 
hyperactive phenotype of T cells through alteration of chromatin structure in the 
promoter region of transcription factors Eomes and Tbet. Using Chromatin-
immunoprecipitation, the presence of HDAC11 in both promoters of Eomes and Tbet 
was determined, along with a decreased acetylation signature of histone 3 in both 
promoters in resting WT T cells [82]. Meanwhile, another study demonstrated that 
deletion or pharmacologic targeting of HDAC11 using a HDAC11 inhibitor (JB3-22) 
could enhance the suppressive function of Foxp3+ Tregs and promotes Treg-dependent 
allograft survival [83].  
 
 
 27 
1.3.2.3 HDAC11 in cancer 
Upon its identification, aberrant up-regulation of HDAC11 has been reported in a 
few cancer cell lines including rhabdomyosarcoma (SJRH30), colorectal carcinoma 
(HCT116), urinary bladder carcinoma (T24), non-small cell lung carcinoma (H1299) and 
oxteosarcoma (SJSA-1) [79]. Recently, another report pointed out that HDAC11 
depletion by siRNA in HCT-116 colon, PC-3 prostate, MCF-7 breast and SK-OV-3 
ovarian cell lines resulted in induced apoptosis and reduced metabolic activity of the 
cancer cells, however, such effects could not be reflected on normal cells [84]. Knocking 
down of HDAC11 in Hodgkin's lymphoma cell lines result in a significant enhanced 
surface expression of OX40L, which is essential for T cell activation and memory 
formation when engage with OX40 receptor B [85]. Additionally, a higher expression of 
HDAC11 that observed in pituitary tumor tissue, which appears to be correlated with 
down-regulation of tumor suppressor P53, possible through the deacetylation of HEY1 
[86]. Another study in neuroblastoma demonstrated that HDAC11 deletion triggered cell 
death through apoptotic programs [87].  
 
1.3.2.4 Other functions of HDAC11 
Earlier studies showed that HDAC11 control DNA replication. Through binding 
Cdt1 during S-phase, HDAC11 deacetylates this molecule and inhibits its ability to 
induce chromatin unfolding thereby limits DNA replication [88]. A recent study had 
demonstrated that HDAC11 can deacetylase Cdc25, a key regulator of cell cycle, via 
direct protein-protein interaction [89]. 
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In addition, expression of HDAC11 was observed at the highest level in mouse 
oligodendrocytes and its expression was increased during brain maturation after birth 
[90]. One study by Liu et al had demonstrated that using HDAC inhibitor (TSA) or 
silencing HDAC11 expression by siRNA result in an increased histone 3 lysine 9 and 
lysine 14 (H3K9/K14) acetylation within the myelin basic protein (MBP) and proteolipid 
protein (PLP) gene promoters in the oligodendrocyte cells, leading to an abruption of 
their maturation and development [91].  
Furthermore, HDAC11 has also been found to be involved in the regulation of 
myc gene along with vitamin D3 [92]. Interestingly, another recent study found out that 
Vitamin D3 could induce the binding rate of Vitamin D receptor (VDR) and HDAC11 to 
the promoter loci of tight junction protein genes, result in the repressing of gene 
expression and the dysfunction of epithelial barrier [93]. 
Although attention and knowledge of HDAC11 is expanding during the past two 
decades, the full functional signature of HDAC11 still needs to be further defined. More 
understanding of the mechanistic role HDAC11 played in cancer and other diseases will 
contribute to further explore its potential as therapeutic targeting in those fields. 
 
1.3.3 Other HDACs 
HDAC1, 2, 3, 5, 6, 7 and 10 can be detected in all tissues whereas HDAC8 and 9 
are mostly expressed in tumor tissues and cells. However, HDAC4 expression is non-
detectable in somatic tissues but can be found in embryonic muscle tissue, which 
indicate that this HDAC is not essential [74].  
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HDAC 1 and 2 only display enzymatic activity within protein complexes such as 
Sin3, nucleosome remodeling and deacetylating (NuRD) complex. Multiple cytokines, 
transcription factors and growth factors are found to be downstream targets of HDAC1, 
2 and 3. Class II HDACs possessed diverse functions among the family. Among all the 
class II members, HDAC6 is the most studied and one of the two HDACs contained two 
deacetylase domains. HDAC6 was found to regulate various pathways related with 
autoimmune disease and cancer, which made it attractive pharmacological targets.  
A typical characteristic of human cancer is the aberrant regulation of DNA 
methylation and histone modification, especially histone acetylation. It is not surprising 
that HDACs are believed to play an important role in cancer progression. Increased 
HDAC activity is observed in many cancers possibly through recruitment of HDACs to 
specific promoters of tumor suppressor genes. Moreover, up-regulation of HDACs 
expression is observed in many cancers. For instance, HDAC1 overexpression is found 
in breast, colon, gastric, and prostate cancer [94-97], whereas HDAC2 is over-
expressed in cervical, colorectal, and gastric cancer [98, 99]. HDAC3 up-regulation is 
reported in colon cancer and HDAC6 in breast cancer [95, 100]. These findings indicate 
that HDACs could be potential targets for cancer treatment.   
 
1.3.4 HDAC inhibitors 
HDAC inhibitors (HDACi) are most considered as promising cancer therapeutics 
along with its crucial role in treating immunological diseases such as viral infection and 
neurological disorder [101]. Besides the ability to inhibit the enzymatic activity of 
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HDACs, HDAC inhibitors also have the potential to target non-histone proteins in order 
to inhibit angiogenesis, cell proliferation and also stimulate cell-cycle arrest [102, 103]. 
Based on the chemical structure, the HDAC inhibitors can be classified into hydroxamic 
acid, benzamides, aliphatic acid and cyclic peptides, electrophilic ketones and 
miscellaneous compounds [104].  
In the past, the most commonly known HDAC inhibitors usually target multiple 
HDACs. This can bring challenges to identify whether the effect of those inhibitors is 
due to inhibition of a particular HDAC activity or in combination of multiple HDACs. 
Moreover, several HDACs are believed to interact or depend on each other to achieve a 
biological outcome, which suggest that even a putative specific HDAC inhibitor could 
potentially develop broader effect than anticipated. Currently, HDACi is observed to 
regulate various cellular or molecular effects in antitumor, immunological and 
neurological responses.  
A lot of questions remained unanswered in regarding to the direct anti-tumor 
effect of HDAC inhibitors. However, it is generally acknowledged that HDACis directly 
effect on tumor cell through multiple pathways such as: 1) induced cell death through 
induction of apoptosis, enhanced production of ROS, accumulation of DNA damage, 2) 
induced cell cycle arrest, 3) induced senescence, 4) reversal of differentiation blocked 
by fusion protein in AMLs, 5) induction of autophagy and 6) enhanced tumour 
immunogenicity such as antigen-presenting capacity (reviewed in [75]). A few HDAC 
inhibitors have been approved for cancer therapy by the US Food and Drug 
Administration (FDA) in recent few years, namely suberoylanilide hydroxamic acid 
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(SAHA, 2006), romidepsin (2009) and belinostat (Beleoda1, 2014), in treatment of T-cell 
lymphoma[105, 106] [107]. 
Many studies demonstrated that HDACs expression and function influence the 
immune response under multiple pathological conditions including cancer. Considering 
the wide spectrum impact of HDACis on different aspects when used as an oncology 
drug, it could potentially achieve its best effect if a particular HDACi could target tumor 
cells and induce anti-tumor immune response simultaneously. A few recent studies 
have shown enhanced tumor antigenicity after treatment with HDAC inhibitor. For 
instance, acute myeloid leukemia (AML), human neuroblastoma and mouse 
plasmacytoma cells treated with HDACis such as TSA, trapoxin A or sodium butyrate 
result in an up-regulation of MHC class I and MHC class II proteins, CD40, CD80, CD86 
as well as adhesion molecule-1 (ICAM1) [108, 109]. Moreover, HDACi such as TSA, 
SAHA and sodium butyrate has been shown to induce the expression of MHC class I 
related chain A (MICA) and chain B (MICB), which are ligands for natural killer group 2 
member D activating receptor on NK, CD8+ T cells, result in increased tumor-targeted 
destruction [110, 111]. Additionally, TSA can induce the proliferation of cytotoxic CD8+ 
T cell and NK cells through enhanced expression of MHC class II and CD40 on B16 
melanoma cells [112]. The antitumor immunity by HDACi SAHA could also result in 
decreased serum level of pro-inflammatory cytokines such as TNF-α, IL-1 and IFN-γ in 
an allogeneic GVHD model [113].  
New HDACi compounds have been developed rapidly during the past few years. 
However, the mechanisms for HDAC inhibitors to augment tumor rejection through 
either direct target or immunomodulatory effect are not fully understood by far. As for 
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the newest identified member of the HDAC family, only a handful of inhibitors have been 
reported to target HDAC11 with an unknown specificity feature. Recent work from our 
group and other laboratory had uncovered a novel regulatory role of T cell function by 
HDAC11, implicated its potential therapeutic value. However, an earlier study from our 
lab demonstrated an opposite role of HDAC11 by enhancing the suppressive ability of 
MDSCs, result in a pro-tumor effect. Given the complexity of the immunomodulatory 
role played by HDAC11, the next two chapters of this dissertation will be dedicated to 
present our recent work on how HDAC11 regulating immune response under different 
pathological conditions. 
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Chapter 2: Essential Role for Histone Deacetylase 11 (HDAC11) in Neutrophil 
Biology1 
 
2.1 List of Abbreviation  
APCs: Antigen Presenting Cells  
APL: Acute Promyelocytic Leukemia  
ATCC: American Type Culture Collection  
ATRA: All Trans-Retinoic Acid  
CBA: Cytometric Bead Arra  
CBC: Complete Blood Count  
ChIP: Chromatin Immunoprecipitation  
CXCL2: Chemokine (C-X-C motif) Ligand 2, Also known as Macrophage Inflammatory 
Protein 2-alpha (MIP2-a)  
CXCR2: Chemokine (C-X-C motif) Receptor 2, also known as Interleukin 8 Receptor 
Beta (IL8Rb)  
                                                          
1 This chapter has been previously published (Chen J, Sahakian E et al. J Leukoc Biol. 
2017 Aug; 102(2):475-486.) and utilized with permission from the publisher. 
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DCs: Dendritic Cells  
E. coli: Escherichia Coli  
eGFP: Enhanced Green Florescent Protein  
FBS: Fetal Bovine Serum  
HDACs: Histone Deacetylases  
HDAC11: Histone Deacetylase 11  
HDAC11KO: HDAC11 Knock-out  
IL-1b: Interleukin-1 beta  
IL-6: Interleukin-6  
IP: Intraperitoneally  
LPS: Lipopolysaccharides  
mABs: Monoclonal Antibodies  
MDSCs: Myeloid-derived Suppressor Cells 
MGAL: Murine Genetic Analysis Laboratory  
MIP2: Macrophage Inflammatory Protein 2-alpha (MIP2-a)  
MPO: Myeloperoxidase  
mRNA: Messenger RNA  
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NETs: Neutrophil Extracellular Traps   
PBS: Phosphate Buffered Saline  
PNs: Peritoneal Neutrophils  
qRT-PCR: Quantitative Reverse Transcriptase-polymerase Chain Reaction  
RACE: Rapid Amplification of cDNA Ends  
RFP: Red Fluorescent Protein 
TNF-alpha: Tumor Necrosis Factor Alpha 
WT: Wild-type 
 
2.2 Abstract 
Epigenetic changes in chromatin structure have been recently associated with 
the deregulated expression of critical genes in normal and malignant processes.  
HDAC11, the newest member of the histone deacetylase family of enzymes, functions 
as a negative regulator of IL-10 expression in antigen presenting cells (APCs) as 
previously described by our lab. However, at the present time its role in other 
hematopoietic cells, specifically in neutrophils, has not been fully explored. In this report 
for the first time we present a novel physiological role for HDAC11, as a multifaceted 
regulator of neutrophils. Thus far, we have been able to demonstrate a lineage-
restricted over-expression of HDAC11 in neutrophils and committed neutrophil 
precursors (promyelocytes). Additionally, we show that HDAC11 appears to associate 
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with the transcription machinery, possibly regulating the expression of inflammatory and 
migratory genes in neutrophils. Given the prevalence of neutrophils in the peripheral 
circulation, and their central role in the first line of defense, our results highlight a unique 
and novel role for HDAC11. Considering the emergence of new selective HDAC11 
inhibitors, we believe that our findings will have significant implications in wide range of 
diseases spanning malignancies, autoimmunity, and inflammation.   
 
2.3 Introduction 
In humans, the predominant circulating leukocytes—neutrophils, are known to be 
produced at immense numbers, through sequences of increasingly differentiated 
precursor myeloid progenitors in the bone marrow (BM), before entering the 
bloodstream and account for 50-70% of the entire circulating population [114-117]. 
During granulopoiesis neutrophils are produced at the rate of 1 x 1011 each day with a 
significant increase within hours during infections [118], and in patients with various 
cancer [119, 120] and therefore more than half of the BM is devoted to the production of 
these cells at steady state [121]. Neutrophils play a pivotal and well-defined role in the 
host defense where they eradicate invading microorganisms [122], and even though 
they have been labeled short-lived, new in vivo deuterium labeling analysis has 
revealed that these cells may have a circulatory life span of up to 5 days [123]. 
Moreover, it is known that neutrophils can influence the immune response by way of 
communicating with dendritic cells (DCs), macrophages [124, 125] as well as B cells 
[126] and T cells [127]. In fact an accumulating series of evidence also suggests that 
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neutrophils  have the potential to gain phenotypic as well as functional properties 
classically assigned to APCs [128, 129], and in the presence of cancer appose tumor 
progression [114, 130] conversely given the appropriate signals, regulate tumor growth 
[131-134].  These antagonistic populations of neutrophils referred to as N1—tumor 
inhibiting and N2—tumor promoting, probably exist as a dynamic array of activation 
states, rather than only two distinct populations [130, 135].  Additionally, neutrophils can 
form structures called NETs (neutrophils extracellular traps) which are involved in a 
process called NETosis—a contributor of innate immunity and induced or stimulated by 
infection, inflammation, trauma, cytokine production, activated platelets, autoantibodies 
and pathogens [136-140]. In recent years, NETosis has been identified as an additional 
pathway of programmed cells death [141] during which nuclear chromatin relaxes and 
forms fibrous web-like structures composed of DNA and histone associated granular 
proteins [138, 142]. Therefore, it is of no surprise that these cells can also damage cells 
and tissues of self (host), highlighting the importance of regulating genes functionally 
responsible for these pathological occurrences [143, 144]. Regulation of neutrophil 
function and differentiation in particular genes involved in the inflammatory responses 
and chronic diseases, are mostly regulated at the transcriptional levels [145]; and 
subsequently an identification of factors involved in these processes would offer 
significant insight into the molecular mechanisms governing functional outcome. For 
number of years, regulation of normal and malignant hematopoiesis by epigenetic 
factors has shown to be an area of significant interest [146, 147]. Epigenetic changes in 
chromatin structure have been associated with the deregulation of critical genes in 
normal as well as malignant hematopoiesis [148, 149]. Histone deacetylases (HDACs)  
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alter chromatin by deacetylation of histone tails, resulting in transcriptionally inactive 
chromatin [150]. HDAC inhibitors have also been identified to alter cytokine production 
profile [151], ultimately influencing the fate and expansion of hematopoietic cells [148, 
152]. However, presently the exact role of specific HDACs in regulation of 
hematopoietic processes is yet to be elucidated. Moreover, it has been demonstrated 
that cytokine production by myeloid cells is regulated by changes in the acetylation 
status of specific gene promoters [153, 154]. HDAC11 has been described as a 
negative regulator of IL-10 expression in myeloid cells [80]. Also, it has been shown that 
lack of HDAC11 increases the suppressive capacity of myeloid derived suppressor cell 
(MDSC) [155]. HDAC11, the most recently identified HDAC, is the sole member of the 
Class IV HDAC sub-family [79].  The functional role of HDAC11 remains poorly 
characterized.  Initially it was believed that HDAC11 had a limited tissue expression 
restricted to kidney, heart, brain, skeletal muscle, and testis [79]; but it has recently 
been documented to also be expressed in hematopoietic cells, where it plays an integral 
role in the regulation of immune tolerance through its action in antigen presenting cells, 
However at the present time, its regulatory role in myeloid differentiation and specifically 
neutrophil function is yet to be characterized.  In this manuscript, we reveal a previously 
unknown role of HDAC11 which may involve the regulation of neutrophil function. Here 
we demonstrate that expression of HDAC11 correlates with neutrophil maturation, 
migration, and phagocytic function. We also show that HDAC11 may be involved in the 
transcriptional machinery of IL-6, TNF-alpha, and CXCR2/CXCL2.  
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2.4 Material and Methods 
 
2.4.1 Mice and cell lines: C57BL/6 wild-type mice were purchased from Charles 
River laboratories, Tg-HDAC11-eGFP reporter mice [156] were provided by Nathaniel 
Heintz through the Mutant Mouse Regional Centers, and HDAC11KO kindly supplied by 
Merck and obtained from Dr. Seto’s lab respectively. All strains of mice were housed in 
the same designated room at the animal facility (Stabile Research-Moffitt Cancer 
Center), were kept in pathogen-free condition, and handled in accordance with the 
requirements of the Guideline for Animal Experiments. HL60 acute promyelocytic 
leukemia (APL) cell line was purchased from American Type Culture Collection (ATCC) 
and cultured and maintained in RPMI with 10% FBS, at 5%CO2 and 37°C. Aging 
HDAC11KO and C57BL/6 wild-type mice were housed in the same room, under 
identical conditions (mentioned above) for 18 months (n=5/group and strain). 
 
2.4.2 Quantitative Reverse Transcriptase-Polymerase Chain Reaction (qRT-
PCR): Total RNA was prepared from centrifugally pelleted and pre-sorted cells (RNeasy 
mini columns and RNAse free DNAse, Qiagen, Valencia, CA). cDNA was prepared 
using iScript cDNA Synthesis Kit (Bio-Rad) and qRT-PCR reactions were conducted 
using the SYBR green two-step qRT-PCR (Bio-Rad) with transcript-specific primers 
(Supplied upon request) and cDNA from samples as templates. qRT-PCR amplification 
reactions were resolved on CFX iCycler (Bio-Rad) and fold changes were quantified (2 - 
 C t ) [157]. Primers used TNF-alpha Forward (CCGATGGGTTGTACCTTGTC) 
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Reverse (AGATAGCAAATCGGCTGACG), IL-6 Forward 
CCGGAGAGGAGACTTCACAG) Reverse (TCCACGTTTCCCAGAGAAC), 18s Forward 
(GTAACCCGTTGAACCCCATT) Reverse (CCGTCCAATCGGTAGTAGCG), CXCL2 
Forward (TCCAGAGCTTGAGCGTGACG) Reverse (TTCAGGGTCAAGGCAAACTT), 
CXCR2 Forward (TCTGCTACGGGTTCACACTG) Reverse 
(ACAAGGACGACAGCGAAGAT). 
 
2.4.3 Flow Cytometry: Flow cytometric analysis of bone marrow aspirates was 
performed using fluorochrome-labeled monoclonal antibodies (mAbs; anti-CD3, -CD4, -
CD8, -CD19, -NK1.1, -CD11b, -Ly6G, -CD45, -CD117, -CD127, -CD11C, -Ly6G) 
Becton Dickinson, San Jose, CA and eBiosciences, San Diego, CA)  and the vitality dye 
4',6-diamidino-2-phenylindole (DAPI, Sigma).  Data was acquired on an LSRII 
cytometer (Beckman Coulter), at least 10,000 events, of the smallest population of 
interest, were collected using an LSR II (BD) and subsequently analyzed using Kaluza 
(BD) and FlowJo software 10.0.07r2 (TreeStar). Annexin V Flow cytometry was 
performed utilizing BD’s LSRII flow cytometer using purified peritoneal neutrophils from 
wild-type C57/BL6 and HDAC11KO mice. A FITC conjugated Annexin V antibody and 
the DNA dye Propidium Iodide were used in conjunction with FACS buffer containing 
and Ca/Mg. Gates were created for the analysis of Apoptotic, Viable and Dead cells 
from total cells. Data was collected to a limit of 10,000 events of the population of 
interest. 
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2.4.4 Immunoblotting: The cells were lysed in a lysis-buffer containing 50 mM 
Tris, 280 mM NaCl, HCL PH 8.0, 0.5% Igepal, 5 mM MgCl2, 10% glycerol and 10X 
protease inhibitor (Roche), phosphatase inhibitor (Santa Cruz Biotechnology). Next , 
lysates were sonicated for 8 min (on ice---for 2 cycles of 30s on, 30s rest) and then 
mixed with 4× gel loading buffer and boiled for 10 min. Samples were then resolved on 
10% gels and transferred to nitrocellulose membranes. Membranes were blocked with 
5% milk-PBS-Tween. Bands were detected by scanning blots with an LI-COR Odyssey 
imaging system. Anti-GAPDH (68795) was purchased from Sigma Aldrich. Anti-b-actin 
(sc-47778) was purchased from Santa Cruz Biotechnology. Anti-HDAC11 (3611P-100) 
was purchased from BioVision Incorporated. 
 
2.4.5 Harvesting and in vitro culturing of mouse peritoneal neutrophils:  
C57BL/6 wild-type or HDAC11KO mice (8 weeks old, female) were injected 
intraperitoneally (ip) with 1 mL sterile 5% Thioglycollate solution (BD).  Mice were 
euthanized and peritoneal cavity was flushed immediately. The cavity was flushed with 
10 mL ice-cold RPMI-1640 medium (HyClone). Cells from the initial wash were pelleted 
and neutrophils were positively selected using biotin anti-mouse Ly-6G antibody 
(127604, Biolegend) and Mouse Biotin Selection Kit (EasySep, Stemcell Technologies). 
The peritoneal neutrophils were cultured in 6-well (5 × 106 cell/mL) plates, in complete  
RPMI-1640 medium in presence of 10% fetal bovine serum (HyClone) and 1% Penicillin 
Streptomycin (Corning), stimulated with 2.5 µg/mL Lipopolysaccharides (LPS) (L2880, 
Sigma). The purity of the peritoneal neutrophils was about 90% after selection. 
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2.4.6 Migration assay analysis: Medium (25 µL) (control Medium) containing 
serum-free medium or chemokine MIP2 (10 µg/mL) was loaded into the lower chambers 
of Transwell system. 50 µL of cells suspension (1×106/mL or 2×106 /mL) in 10 % FBS 
RPMI 1640 medium was added to the upper compartment of the chemotaxis chamber. 
The two compartments were separated by a 5-µM pore size polycarbonate filter. 
Spontaneous migration was determined as the movement of cells toward the control 
medium. 
2.4.7 Chromatin Immunoprecipitation: Mouse peritoneal neutrophils (PNs) 
(3×107) were cross-linked with 1% formaldehyde (F8775-25ML, Sigma) for 10 minutes 
at room temperature. Then the cross-linking was stopped by 0.125 M glycine for 10 
minutes at room temperature. The cells were washed twice with PBS and proceed with 
sample preparation. The cell pellet was lysed by 1 mL of lyse buffer (50 mM HEPES pH 
7.8, 3 mM MgCl2, 20 mM KCl, 0.25% Triton X-100, 0.5% NP-40) on ice for 10 minutes. 
The cell lysate was transferred to a “Dounce Homogenizer” and 25 strokes were applied 
using the loose pestle A. The cell pellet was washed once with 1 mL wash buffer (10 
mM Tris-HCl pH 8.0, 1 mM EDTA, 200 mM NaCl). The pellet was resuspended in 600 
uL sonication buffer (50 mM HEPES pH 7.8, 140 mM NaCl, 1 mM EDTA, 0.5% SDS, 
1% Triton X-100). The samples were sonicated and centrifuged for 10 minutes. The 
lysate was diluted at 1:10 to dilution buffer I (50 mM HEPES pH 7.8, 140 mM NaCl, 
1mM EDTA, 1% Triton X-100), pre-cleared using Protein A Agarose beads (16-156, 
Millipore), incubated with rabbit anti-HDAC-11 antibody cocktail (3611P, BioVision and 
H4539-200UL, Sigma) on a rotator at 4°C overnight. Biotin-conjugated normal rabbit 
IgG-B (SC-2763, Santa Cruz Biotechnology) was added at the same amount of rabbit 
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anti-HDAC-11 antibody cocktail in parallel of each sample and incubated on a rotator at 
4°C overnight. Then 50 µL protein A Agarose beads was applied to each sample and 
incubated at 4°C for 4 hours. The beads were then washed twice each with dilution 
buffer I, dilution buffer II (50 mM HEPES pH 7.8, 500 mM NaCl, 1 mM EDTA, 1% Triton 
X-100), LiCL buffer (20 mM Tris-HCl pH 8.0, 250 mM LiCl, 1 mM EDTA, 0.5% Triton X-
100), and TE buffer (10 mM Tris-HCl pH 8.0, 1 mM EDTA). Then the beads were eluted 
in 100 µl elution buffer (50 mM Tris-HCl pH 8.0, 1 mM EDTA, 1% SDS) and incubated 
at 65°C for 15 minutes and the immunocomplexes were collected in the soluble fraction. 
NaCl was added to a final concentration 200 mM and the crosslinking was reverted by 
incubating at 65°C for overnight. Then RNAse A (158922, Qiagen) was added to 20 
µg/mL to each sample and incubated at 37°C for 30 minutes. Proteinase K (EO0491, 
Thermo Scientific) was then added at 100 µg/mL and incubated at 42°C for 2 hours. 
DNA was purified by using QIAquick PCR Purification Kit (28104, Qiagen) and purified 
DNA was eluted in 100 µL TE buffer for analysis by qRT-PCR. 2 µL of DNA was used 
for each qRT-PCR reaction. The following PCR primers were used: TNF alpha Forward 
(CTCGGAAAACTTCCTTGGTG), TNF alpha Reverse 
(CGATGGAGAAGAAACCGAGA), IL-6 Forward (TCTGCAGAGTGAAGAAGCTGA), IL6 
Reverse (GATTCCAGGCTGAAAGTAGGC), CXCL2 (MIP-2) Forward 
(GGCTAGAACTGAGGGCTAC), CXCL2 (MIP-2) Reverse 
(ACATCCATTCTTGTCCCACTG), CXCR2 Forward (CCTCTGACTCCCACACATCT), 
CXCR2 Reverse (GCTTGCTGTGCTTTTGGTTT).  
2.4.8 Phagocytosis assay: Upon euthanasia, 1mL of blood was obtained from 
an experimental mouse via cardiac puncture with a heparinized syringe.  Blood was 
 44 
centrifuged at 2,000 RPM for 2 minutes in a microcentrifuge tube and Sera was 
aspirated and added to a single tube of lyophilized pHrodo Red E. coli BioParticles (Life 
technologies).  The BioParticles were vortexed and then incubated for 30 minutes in a 
37ºC water bath for optimal opsoninization.  BioParticles were centrifuged at 2,000 RPM 
for 2 minutes and washed twice with PBS (pH 7.4) w/o Ca and Mg and resuspended in 
2 mL of RPMI with 10% FBS. Purified neutrophils were resuspended at 1 x 106 cells per 
mL and plated at 100 µL per well, in quadruplicate, in a 96 well flat bottom TC treated 
plate per mouse. BioParticles were added to the plate immediately before being placed 
into Incucyte High Throughput Live Cell Microscope System for detection of red 
fluorescent protein (RFP) expression. 
2.4.9 Incucyte real-time microscopy analysis:  Cells in a 96 well plate were 
imaged through a 10× objective lens at 5 minute intervals for 3 hours using the Incucyte 
Zoom HD live cell imaging system (Essen Bioscience, Michigan, USA).  The system is 
located in a 37ºC /5% CO2 cell culture incubator to maintain proper incubation 
conditions.  Analysis was performed using the default red fluorescence processing 
definition within the Incucyte Zoom 2014B software.  The number of red cells and 
confluency of red fluorescence was extracted from the images and export the excel 
format.  
2.4.10 Cytometric Bead Array: This assay involves measurement of secreted 
cytokines in the media by flow cytometry. Briefly, 100 µL of supernatant from cells 
stimulated with or without LPS were collected as specific time-points and IL-6 and TNF-
alpha levels were measured following manufactures recommended protocol CBA kitTM; 
(BD Biosciences, San Jose, Ca). 
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2.4.11 Sepsis model: C57BL/6 wild-type and HDAC11KO mice were injected 
with 15 mg/Kg of LPS (L4391-1MG Sigma) via tail vein (TV) in 100 µL volume and 
observed for signs of sepsis (abnormal posture/positioning, partial paralysis, failure to 
respond to stimuli, head tilt, circling, impaired locomotion, non-purposeful movement, 
hypoactivity, hyperactivity, restlessness, self-trauma, aggressiveness, isolation from 
cage mates, shallow, rapid and/or labored breathing, cyanosis, piloerection, matted hair 
coat, lack of inquisitiveness, hunched posture and/or vocalizations)  3 times daily.  
2.4.12 RACE analysis: This experiment was out-sourced to murine genetic 
analysis laboratory, mouse biology program at University of California, Davis. Detailed 
protocol will be provided upon request. 
2.4.13 Statistical Analysis: Unless otherwise specified, the statistical 
significance between values was determined by student’s t test. Data were expressed 
as the mean ± SD. Probability values of p ≤ 0.05 were considered significant.   
 
2.5 Results 
2.5.1 HDAC11 is differentially expressed in various stages of myeloid 
differentiation 
It has previously been reported that HDAC11 is a negative regulator of IL-10 
production in myeloid cells. Here, we examined the expression of HDAC11 in 
myelopoiesis. To follow the dynamic changes in HDAC11 transcriptional activation, we 
utilized HDAC11 promoter-driven eGFP reporter mice (Tg-HDAC11-eGFP) [156], where 
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eGFP expression is indicative of HDAC11 transcription. Using multiparameter flow 
cytometric analysis, as seen in Figure 2.1A, in the bone marrow compartment, we were 
able to determine that expression of HDAC11 is markedly increased in promyelocytes 
when compared to earlier progenitors and further amplified in the neutrophils when 
compared to myeloblasts.  Interestingly, expression eGFP and consequently of 
HDAC11 in monocytes was negligible when compared to promyelocytes and 
neutrophils (Figure 2.1A). The lymphocytes also show a moderate expression of 
HDAC11 transcript. Expression of HDAC11 protein was confirmed by immunoblotting 
analysis in flow-sorted monocytes, promyelocytes and neutrophils (Figure 2.1B top 
panel).   Quantitative mRNA analysis confirmed our findings by demonstrating an 
increase in the expression HDAC11 message (fold changes are normalized to the 18s 
house-keeping gene for each sample) and further validated the Tg-HDAC11-eGFP 
reporter mouse model (Figure 2.1B lower panel) used in our experiments. Additionally, 
we further validated these results by quantifying the mRNA expression of eGFP in the 
same samples and were able to demonstrate that expression of HDAC11 is 
concomitant with the expression of eGFP message (Figure 2.1C).  To ensure that our 
data was not an artifact of the eGFP reporter mouse model, we flow-sorted monocytes, 
promyelocytes, neutrophils, and lymphocytes from a C57BL/6 wild-type mouse and 
examined the expression of HDAC11 message (Figure 2.1D). The results confirmed our 
previous findings in the Tg-HDAC11-eGFP reporter mouse and consequently the 
neutrophil population expressed significantly higher levels of HDAC11 when compared 
to the rest of the sub-populations. Next, we purchased source leukocytes (OneBlood, 
Florida Blood bank) collected from volunteer normal donors and isolated (flow-sorted 
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cell populations) monocytes and neutrophils. Quantification of HDAC11 expression 
observed in this figure show parallel results mirroring what we had previously seen in 
our murine models where neutrophils had higher expression of HDAC11 message 
(Figure 2.1E lower panel). Immunoblotting analysis confirmed the expression of 
HDAC11 in the neutrophils when compared to the monocyte population (Figure 2.1E top 
panel). 
 
Figure 2.1 HDAC11 message is differentially expressed in various stages of 
myelopoiesis. (A) Dynamic visualization of HDAC11 message using HDAC11-eGFP 
transgenic mouse in myeloid compartments. Bone marrow was extracted from Tg-
HDAC11-eGFP (As well as CD57B/6 mice as control- non-eGFP expressing cells; gray 
histogram markings) and cells were labeled (as indicated above) with specific cell 
surface markers for identification of each population. HDAC11 expression was 
determined by flow cytometry analysis of eGFP reporter gene expression, where the 
 48 
expression of eGFP protein corresponds to the activation of HDAC11 transcriptional 
machinery. (Representative presentation from 2 individual experiments) (B) Monocytes, 
promyelocytes, and neutrophils from Tg-HDAC11-eGFP mouse bone marrow cells were 
sorted using FACS-Aria (BD) device with 99% purity. Cells were lysed using TriZoL 
reagent (Invitrogen) as well as RIPA buffer (Cell Signaling) and RNA as well as protein 
was extracted respectively. Immunoblotting was performed using 10% SDS gel and 
image was resolved using Dura ECL reagent (Pierce) (Top image) and qRT-PCR 
analysis was performed using HDAC11 primers (bottom graph). Sorted cell populations 
were also morphologically confirmed (Lower panel). (C) Co-expression of HDAC11 
message and eGFP message was confirmed by qRT-PCR using eGFP primers. (Error 
bars = S.E.M; data representative of 3 individual experiments n=3) (D) Monocytes, 
promyelocytes, neutrophils, B-cells, and T cells were sorted from C57BL/6 wild-type 
mouse bone marrow cells using FACS-Aria (BD) device with 98% purity. Cells were 
lysed using TriZoL reagent (Invitrogen) and RNA was extracted. qRT-PCR analysis was 
performed using HDAC11 primer. This was done to confirm HDAC11 expression profile 
in a non-transgenic setting.  (Error bars = S.E.M; data representative figure from 3 
individual experiments n=3). (E) Four normal human donor peripheral blood source 
leukocyte samples (Purchased from OneBlood Florida) were sorted for monocytic and 
neutrophylic populations using FACS-Aria (BD) device with 96% purity and then 
examined for the expression of HDAC11 message using qRT-PCR analysis and the fold 
change between neutrophils and monocytes were normalized to the lowest expressing 
monocytic population. (Error bars = S.E.M, n=4)  Note: In figures B, C, D, and E sub-
populations were compared and normalized to monocytes (Since they have the lowest 
expression of HDAC11). 
 
2.5.2 Expression of HDAC11 is significantly increased in leukemic cells 
upon differentiation  
Utilizing HL60 acute promyelocytic leukemia (APL) cell line model and upon in 
vitro maturation and differentiation of these cells using all trans-retinoic acid (ATRA) 
stimulation, we observed an increase in the expression of HDAC11 message (Figure 
2.2A bottom) and protein (Figure 2.2A top) as demonstrated. These differentiated HL60 
cells also exhibited neutrophil-like segmentation and over-expression of maturation 
markers such as CD11b, and myeloperoxidase (MPO) (Figure 2.2B).  
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Figure 2.2 Expression of HDAC11 in acute promyelocytic leukemia samples (APL) and 
functional consequences of its manipulation in this model. (A) HL60 cells were treated 
with All Trans Retinoic Acid (ATRA) for 72hrs and the expression of HDAC11 message 
was measured by qRT-PCR and the differentiation of HL60 cells to granulocytic-like 
cells were examined by morphological analysis (Left) Error bars = S.E.M; 
(Representative figure from 3 individual experiments) . (B) The differentiation of HL60 
cells to granulocytic-like cells were examined using Myeloperoxidase (MPO-a marker 
for cell’s gain of granularity) (Top) as well as CD11b expression (Bottom). 
(Representative figure from 3 individual experiments).  
 
2.5.3 Lack of HDAC11 markedly increases the expression of pro-
inflammatory cytokines 
HDAC11 is restricted mainly to the nucleus, and its expression appears to be 
tissue specific with higher expression in brain, heart, testis, and skeletal muscle [79], 
however its precise function in myeloid compartment and specifically in the neutrophils 
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is yet to be elucidated. In the previous experiments, we utilized germ-line HDAC11 
knock-out mice (HDAC11KO) (Merck Pharmaceutical). HDAC11KO (C57BL/6 
background) mice were developed using Lox/CRE technology to remove a floxed exon 
3, a portion of the histone deacetylase catalytic region. In our Figure 2.3A, we 
demonstrate our method of positively genotyping the HDAC11KO mice. Since these 
mice will still transcribe a truncated mRNA sequence (excluding exon3), and to further 
validate this mouse model, we designed a special HDAC11 primer set that was within 
the excised exon3 region of HDAC11 gene. As seen in supplementary figure, 
HDAC11KO mice have no amplified HDAC11 amplicons demonstrated by qRT-PCR 
analysis when compared to C57BL/6 wild-type counterparts (Figure 2.3B). Also, 
immunoblotting analysis suggested that the expression of HDAC11 is absent in cells 
isolated from HDAC11KO mice (Figure 2.3C).  Taking a step further, we sent samples 
from two C57BL/6 wild-type and two HDACK11KO mice to Murine Genetic Analysis 
Laboratory (MGAL), Mouse Biology Program at University of California, Davis for Rapid 
Amplification of cDNA ends (RACE-Seq). The data confirmed that the HDAC11KO mice 
are devoid of exon3 on the HDAC11 gene sequence. 
Recently, it has been demonstrated that epigenetic factors such as HDACs have 
been known to affect regulation of genes involved in inflammatory responses [158]. 
Subsequently, we decided to investigate whether lack of HDAC11 had any functional 
consequences in the neutrophil population. To do this, we isolated peritoneal 
neutrophils (PNs) from both HDAC11KO as well as C57BL/6 wild-type mice; 18 hours 
post 5% thioglycollate injection.  In vitro, cells were treated with 2.5 µg/mL of  
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Figure 2.3 (A) Schematic representation of HDAC11KO mouse development and 
genotyping methods for proper identification of mouse colony. (B) qRT-PCR analysis of 
HDAC11 expression (using exon3-designed primers) in brain and spleen of C57BL/6 
wild-type and HDAC 11KO mice (n=3). (C) Expression of HDAC11 protein in brain and 
testes of C57BL/6 wild-type and HDAC 11KO mouse. 
 
lipopolysaccharide (LPS) for 2 and 4 hours and the samples were analyzed for TNF-
alpha and IL-6 message and protein expression. Results revealed that in the absence of 
HDAC11, neutrophils became more inflammatory as seen by the mRNA expression 
level of TNF-alpha and IL-6 at every time-point (Figure 2.4A).    These findings were 
further confirmed by cytometric bead array (CBA) protein analysis where both cytokines 
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showed higher level of expression when compared to the C57BL/6 wild-type 
counterparts (Figure 2.4B). We were also interested to see whether lack of functional 
HDAC11 changed the normal distribution of hematological cells in the peripheral blood. 
Briefly we collected peripheral blood from HDAC11KO as well as their normal 
counterparts C57BL/6 wild-type mice (sub-mandibular blood collection) and performed a 
complete blood count (CBC) analysis. Surprisingly, both cohorts—HDAC11KO as well 
as the C57BL/6 wild-type control mice had relatively similar monocytic and granulocytic 
blood count profile (Figure 2.4C).  To our knowledge thus far, there has been no report 
of HDAC11 binding directly to DNA and consequently, there are no direct downstream 
genes that can be signature indicators of this interaction. In experiments for this section 
we also interrogated the possibility of HDAC11 being involved in transcriptional 
regulation of these molecules. Briefly, PNs isolated from C57BL/6 wild-type mice were 
treated with 2.5 µg/mL of LPS for 3.5 hours (the concentration and the time point for 
these experiments were determined by dose titration and time course analysis in 
preceding experiments) and then the cells were processed for Chromatin 
immunoprecipitation (ChIP) assay. In Figure 2.4D, ChIP data suggests that HDAC11 
may be recruited to the TNF-alpha and IL-6 transcriptional complex. To demonstrate 
that this observation was specific to HDAC11 being possibly recruited to the promoter 
region of TNF-alpha and IL-6, we performed a similar ChIP analysis in mice using 
HDAC11KO PNs which showed no recruitment of HDAC11 to the promoter regions of 
TNF-alpha and IL-6 interpreted by no change in the enrichment ratio when comparing 
LPS stimulated samples to the non-stimulated controls (Figure 2.4E).  
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Figure 2.4 Phenotypic consequences of HDAC11 deficient peritoneal neutrophils. (A) 
Peritoneal neutrophils (PNs) from C57BL/6 wild-type and HDAC11KO mice were 
collected post thyoglycolate injection (5% at 18hrs). The cells were treated with 2.5 
µg/mL of LPS for 2, and 4hrs. Expression of inflammatory genes TNF-alpha and IL-6 
were measured by qRT-PCR. (B) Protein concentrations for TNF-alpha and IL-6 were 
measured by cytometric bead array (CBA) analysis.  (C) Complete blood count from 
C57BL/6 wild-type and HDAC11KO (n=6 per group). (D)  The recruitment of HDAC11 
protein to chromatin fragments of TNF-alpha and IL-6 promoters were analyzed using 
the PfaffI method [157] and are presented relative to input before immunoprecipitation 
and the enrichment ratio was normalized to the IgG control (PNs isolated from C57BL/6 
wild-type)  (E) PNs isolated from HDAC11KO mice were used in another ChIP assay as 
negative control.   (NT = No LPS incubation). (Error bars = S.E.M; data presented for 
each graph is a representative figure from 2 individual experiments). 
 
2.5.4 Neutrophils isolated from mice lacking HDAC11 demonstrate much 
higher migratory and phagocytic capacity 
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The hallmark of neutrophils in the innate immune system is their capacity to 
migrate to the site of tissue injury and/or infection. In order to interrogate migratory 
capacity of neutrophils lacking HDAC11, we isolated peritoneal neutrophils (as 
mentioned in Figure 2.4) and performed a migration assay.   Briefly, in this assay 
isolated neutrophils were loaded in the upper compartment of the chemotaxis chamber, 
and the serum-free media or chemokine CXCL2-(MIP-2—IL-8 homologue) (10 µg/mL) 
was loaded into the lower chambers of a transwell system, and the assay was 
concluded by detection and calculation of migratory neutrophils. The data suggests that 
neutrophils isolated from the HDAC11KO mice have a significantly higher migratory 
capacity towards a bait chemokine MIP-2 when compared to the wild-type counterpart 
(Figure 2.5A). Next we compared the expression of migratory receptor/chemokines 
such as CXCR2 (Homologue of IL-8 receptor beta) /CXCL2, in HDAC11KO and 
C57BL/6 wild-type mice. In Figure 2.5B we demonstrate a higher endogenous 
expression of mRNA for these molecules in neutrophils lacking HDAC11.    Flow 
cytometry analysis confirmed a significant increase in the protein level of CXCR2 on 
HDAC11KO neutrophils when compared to the C57B/6 wild-type mice (Figure 2.5C), 
however the changes in the CXCL2 protein levels were not significant (data not shown).  
Furthermore we assessed the phagocytic ability of C57BL/6 wild-type versus 
HDAC11KO mouse PNs. Briefly, equal number of PNs from C57BL/6 wild-type and 
HDAC11KO mice were co-cultured with E. coli BioParticles loaded with a pH sensitive 
fluorescent dye. Using live microscopy, we were able to (in real-time) monitor 
phagocytic capacity of PNs from each mice. Data ascertained from these experiments 
demonstrated that PNs from the HDAC11KO mice were functionally more potent  
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 Figure 2.5 Enhanced migratory and phagocytic capacity of HDAC11KO neutrophils. 
(A) Migration assay analysis between C57BL/6 wild-type and HDAC11KO PNs utilizing 
the Transwell system and 2 x 106 per sample. Expression of migratory genes were 
analyzed in PNs isolated from the WT and HDAC11KO mice using qRT-PCR analysis 
(Data generated from 4 individual experiments) **p-value < 0.01, * p-value < 0.05. (B) 
mRNA expression of CXCL2 and CXCR2 were analyzed in both C57BL/6 wild-type and 
HDAC11KO mice at steady state. (Representative figure from 2 individual experiments). 
(C) Expression of surface CXCR2 protein on neutrophils from HDAC11KO vs C47BL/6 
wild-type mice. (D) Phagocytic ability of PNs isolated from both C57BL/6 wild-type and 
HDAC11KO mice were analyzed in the presence of E. coli Bio-Particles loaded with a 
pH sensitive fluorescent dye and analyzed as a measure of cell engulfment and lysis in 
real-time (RFP measurement by microscopy). (Error bars = S.E.M; statistical analysis 
was done using two-way ANOVA **p-value < 0.01, * p-value < 0.05. Data presented is a 
representative figure from 2 individual experiments). (E) The recruitment of HDAC11 
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protein to chromatin fragments of CXCL2 and CXCR2 promoters was analyzed in the 
presence and absence of LPS stimulation. (F) PNs from HDAC11KO mice were used in 
another ChIP assay as negative control.   The values obtained for these ChIP 
experiments were analyzed using the PfaffI method [157] and are presented relative to 
input before immunoprecipitation and the enrichment ratio was normalized to the IgG 
control. (Error bars = S.E.M; representative figure from 2 individual experiments, three 
animals were used for each experiment). 
 
(Figure 2.5D). Given our findings discussed in the above experiments, it was deemed 
necessary to determine if there HDAC11 was being recruited to the promoters of 
CXCR2 and CXCL2. Given our presented data so far, we predict that HDAC11 may be 
a negative regulator of genes involved in migratory response. To examine this 
hypothesis, we performed a ChIP analysis. Briefly, PNs from C57BL/6 wild-type mice 
were treated with 2.5 µg/mL of LPS for 3.5 hours and then the cells were processed for 
ChIP assay. The data indicates that there is recruitment of HDAC11 to the promoter 
regions of CXCR2 and CXCL2 (Figure 2.5E).  To demonstrate that this observation was 
specific to HDAC11, we performed a similar ChIP analysis using HDAC11KO PNs 
which showed no change in the enrichment ratio when comparing LPS stimulated 
samples to the non-stimulated controls. The observed recruitment of HDAC11 to the 
promoter regions is not defined as a direct biding of HDAC11 to the promoter regions 
however, the interrogation of this possibility requires additional and in depth promoter 
binding analysis in the future.   
2.5.5 HDAC11KO mice are more susceptible to LPS induced sepsis when 
compared to C57BL/6 wild-type counterpart 
Sepsis in humans, defined as severe inflammation in the presence of infection, is 
a common syndrome that kills thousands of patients each year [159]. To study this 
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physiological response, murine models have been established and validated. For 
instance, in intoxication models mice are inoculated with proinflammatory 
compounds(noninfections) such as lipopolisaccharides (LPS) [160]. Of note, mice are 
extremely resilient to most types of inflammation when compared to humans, but at high 
doses of LPS within the range of 1-25 mg/kg (1000-10000 X the dose that will cause 
septic shock in humans), mice experience severe inflammatory response and eventually 
succumb to sepsis [161, 162]. Given our observations thus far, it appears that 
HDAC11KO PNs, at steady state, have a higher innate inflammatory nature when 
compared to the C57BL/6 wild-type mice. Therefore, we sought to investigate whether 
there was a difference between the time of inflammatory onset, leading to eventual 
sepsis and death (post LPS inoculation), when comparing HDAC11KO and C57BL/6 
wild-type mice.  Briefly, a cohort of HDAC11KO and age matched C57BL/6 wild-type 
mice (n=8 in each group), were injected with LPS at 15 mg/kg via tail vein. Mice were 
monitored 3 times in 24hrs.  As seen in Figure 2.6, although all mice post LPS 
inoculation showed signs of fatigue and sluggish movements, HDAC11KO  mice 
expired within the first 48hrs of the experiment while the remaining C57BL/6 wild-type 
mice fully recovered and were ultimately euthanized at 72hr time-point to mark the 
termination of the experiment. 
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Figure 2.6 Septic shock experiment comparing HDAC11KO mice and C56BL/6 mice. A 
cohort (n=8) of HDAC11KO and C57BL/6 mice were injected with 15 mg/kg of LPS via 
tail vein. Survival graph representing both groups in time-line up to 72 hours. (Data 
presented is a representative figure from 2 individual experiments). 
 
2.5.6 HDAC11KO mice show bone marrow hypercellularity with 
granulocytic expansion and splenomegaly due to increased extramedullary 
hematopoiesis 
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Emergency granulopoiesis is defined as a well-coordinated de novo production of 
neutrophils due to increased myeloid progenitor cells proliferating in the bone marrow, 
signaled by and during severe infection. The ultimate goal of this physiological 
occurrence is to increase the neutrophil output during an innate immune response.  In 
order to see whether HDAC11KO mice had a more robust production of neutrophils, we 
injected (i.p.) a cohort of HDAC11KO and C57BL/6 wild-type mice with Freund’s 
complete adjuvant (Thermo Scientific) and assessed the expression of granular cells by 
flow cytometry.  Flow cytometery analysis revealed a moderate increase of granular 
cells in the spleen of the HDAC11KO mice when compared to the C57BL/6 wild-type 
mice however this difference was not significant.  Immunohistochemisty (IHC) and H&E 
staining of bone marrow cells from the same mice demonstrated extensive 
hypercelullarity which did not allow decisive identification and quantification of granular 
cells (data not shown). However, when we compared spleen sections from aging 
(18months old) HDAC11KO and C57BL/6 wild-type mice, we observed that the 
HDAC11KO spleens had increased extramedullary hematopoiesis resulting in an 
expanded red pulp (figure 2.7A).  In addition, sections from femoral bones revealed a 
marked bone marrow hypercellularity on aging HDAC11KO mice, mostly due to an 
expansion of maturing neutrophils (figure 2.7B).  
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Figure 2.7 Observation of splenomegaly as well as Hypercellularity with granulocytic 
expansion in BM of HDAC11KO mice. (A)  Representative sections of spleens (H&E 
stain) harvested from aged C57BL/6 wild-type (top) and HDAC11 KO (bottom) mice 
showing a marked expansion of the red pulp (left, x40), due to replacement of the 
mostly lymphocytic red pulp cellularity observed on C57BL/6 wild-type mice  with mostly 
trilinegae extramedullary hematopoiesis on the HDAC11KO mice (right, x400).  (B)   
Representative sections of femurs (H&E stain) harvested from aged C57BL/6 wild-type 
(top) and HDAC11 KO (bottom) mice showing a marked increase in the bone marrow 
cellularity on HDAC11KO mice compared to WT mice (left, x20), mostly due to an 
expansion on maturing neutrophils (right, x200). (n=5 per group)    
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2.6 Discussion 
In myelopoiesis, lineage-specific transcription factors C/EBPα, C/EBPε, PU.1, 
and AML1 cooperatively interact with specific DNA sequence response elements to 
initiate transcription of genes involved in differentiation [121, 163-165]. More recently, 
epigenetic mechanisms such as chromatin modification by acetylation/deacetylation of 
histone tails have been shown to contribute to the regulation of gene expression and 
determination of cell population specificity [166, 167]. Conversely, it has been 
demonstrated that the deregulation of epigenetic mechanisms cause genetic alterations 
which consequently leads to manifestation of diseases such as cancer and 
autoimmunity [102, 168]. More specifically, epigenetic modulations have been reports in 
number of cellular processes involved in neutrophil development and functions 
(reviewed in [147])  including NETosis [169]. 
In this report, the interrogation of the transcriptional activity of HDAC11 in 
myeloid and lymphoid cells, utilizing a HDAC11 promoter-driven eGFP reporter mouse 
model, combined with utilization of lineage-specific markers with multiparametric flow 
cytometry analysis demonstrated a significant over-expression of HDAC11 in 
neutrophils, when compared to monocytes (Figure 2.1A). Moreover, analysis of 
hematopoietic cells isolated from the bone marrow of the Tg-HDAC11-eGFP mice 
revealed an over-expression of HDAC11 at the promyelocyte stage of neutrophil 
differentiation and with a significant increase in the neutrophils. Monocytes showed low 
to undetectable expression of HDAC11 (Figure 2.1B & C). Additionally, our results 
utilizing flow-sorted leukocyte subpopulations from C57BL/6 wild-type mouse bone 
marrow, further confirmed and demonstrated a higher level of HDAC11 expression in 
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promyelocytes and neutrophils compared to monocytes and lymphoid subsets (Figure 
2.1D). Equally, flow-sorted monocytes and neutrophils from normal human donors’ 
source leukocytes showed higher levels of HDAC11 expression in neutrophils, as 
compared to monocyte population (Figure 2.1E). These findings are of interest because 
they suggest that HDAC11 may be a factor during myelopoiesis and consequently play 
a role in the fate of neutrophils. Epigenetic mechanisms such as histone modifications 
play a key role in the control of multiple normal biological processes including 
hematopoiesis as well as alterations leading to many diseases such as autoimmunity 
and cancer [170, 171]. Understanding the role of each specific HDAC in the context of 
the immune system, in different malignancies, will facilitate selective cancer 
immunotherapeutic modalities. Therefore we further examined HDAC11 in a cancer 
model to determine whether this lineage-specific overexpression also applied to 
malignancies using HL60 acute promyelocytic leukemia (APL) human cell line. Our 
findings supported what we had seen in normal processes. Upon in vitro ATRA induced 
differentiation and maturation of APL cells, expression of HDAC11 is increased 
exponentially (Figure 2.2A). Concurrently the expression MPO and CD11b (markers of 
granularization and) were increased (Figure 2.2B) during maturation of APL cells. The 
exploration of the physiologic role of HDAC11 overexpression in neutrophils, utilizing a 
model of germline-HDAC11KO mice demonstrated that purified neutrophils lacking 
HDAC11 displayed an apparent overproduction of TNF-alpha and IL-6 upon stimulation 
with LPS both at message and protein levels, as compared to their C57BL/6 wild-type 
counterparts (Figure 2.4A & B). Our assessment of these collective data suggests that 
HDAC11 may be playing the role of a check-point molecule; where it possibly controls 
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the activation of neutrophils.  Moreover, subsequent data suggests that HDAC11 may 
be associated with the transcriptional machinery of inflammatory molecules TNF-alpha 
and IL-6 as seen by HDAC11-chromatin binding which was demonstrated by ChIP 
analysis (Figure 2.4D & E). Recently, Stammler, et al reported that HDAC11 inhibition 
increases IL-1b in dendritic cells and macrophages through promoting nonanonical 
caspase-8-dependent pathway [172]. In our experiments, ChIP analysis revealed that 
HDAC11 –chromatin binding is distinctive to TNF-alpha and IL-6 and no binding was 
observed for IL-1b (IL-1b data not sown).  Markedly, migration assay analysis also 
demonstrated that neutrophils isolated from HDAC11KO mice exhibit a significantly 
higher migratory rate as well as increased phagocytic activity when compared to the 
C57BL/6 wild-type mice (Figure 2.5A). This observation is highlighted by qRT-PCR 
analysis that showed HDAC11KO mice demonstrate an endogenous over-expression of 
CXCR2 and CXCL2 genes (Figure 2.5B & C).  Moreover, ChIP analysis results suggest 
that HDAC11 may also be recruited to the transcription complex, regulating the 
transcription machinery of CXCR2 and CXCL2 (Figure 2.5E & F). Recently published 
data suggests that HDAC11 has functional network protein association with number of 
biological processes including gene expression [173], therefore highlighting the 
possibility of its involvement in regulating transcription which is yet to be determined.  
Typically, occurrence of severe sepsis also known as septic shock is fatal from 
complications of infection, usually caused by dysregulated inflammatory and immune 
responses.  The onset of sepsis is generally due to a robust innate immune response, 
through enhanced granulopoiesis in the bone marrow and generation of exuberant 
number of neutrophils, and consequently a massive production of pro-inflammatory 
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cytokines [174]. Sepsis remains a serious health issue and therefore identification of 
factors contributing to it is of great interest.   Thus far, numerous studies have labeled 
pan-HDAC inhibitors fundamentally as negative regulators of gene expression for acute 
immune receptors and pathways in innate immune cells [175, 176]. However 
oversimplifying this statement cannot be generally correct since HDAC inhibitors 
depending on tissue type and time of treatment, can have alternative effects on gene 
expression. Consequently, numerous investigators are now focusing on selective HDAC 
inhibitors to narrow the target of interest.  In regards to HDAC11, our observations 
suggest that this HDAC maybe a gatekeeper of inflammatory response in neutrophils. In 
fact, in a murine sepsis model, we were able to show that HDAC11KO mice succumb to 
sepsis much faster than the C57BL/6 wild-type counterparts (Figure 2.6) suggesting the 
possible presence of pre-primed neutrophils in HDAC11KO mice. Additionally, CellTiter-
Blue® viability assay demonstrated a modest decrease in the number of neutrophils 
(isolated from the BM) extracted from HDAC11KO mice in the absence of stimulation 
when compared to the C57BL/6 wild-type counterpart however, a significant decrease in 
the viability of neutrophils isolated from the HDAC11KO mice was observed when these 
cells were stimulated with GM-CSF, compared to C57BL/6 wild-type counterparts 
(Figure 2.8).  Moreover, in aging HDAC11KO mouse experiment we observed 
noticeable increase in the bone marrow cellularity when compared to age-matched 
C57BL/6 wild-type controls mice, which is mostly due to an expansion of maturing 
neutrophils (Figure 2.7).  This is indicative of what we have demonstrated—signifying 
the likelihood of an essential role for HDAC11 in neutrophil biology.  
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Figure 2.8 BM cells from the femurs of age-matched WT (C57BL/6) and/or HDAC11KO 
(C57BL/6) mice (n=4/ mouse strain) were extracted and neutrophils from these samples 
were isolated using the StemCell™ EasySep magnetic selection kit. Each sample was 
plated at equal numbers in triplicates in a 96-well plate. Cells were then treated (or not 
in the control groups) with 50ng/ml of mouse GM-CSF for 9 hours. Next CellTiter-Blue®  
reagent was added to each well and incubated at 37C for 1 hour following by the 
measurement of fluorescent signal  at 560(20)Ex/590(10)Em using a BioTek Cytation 3 
plate reader. (Data is a representative graph from 2 independent experiments). 
 
In recent years, the role of neutrophils has significantly expanded from front-line 
combatants of infection to endowment of anti-tumor immunity [177, 178]. In contrast, 
recent evidence suggests a novel pro-tumor function for these cells [124, 179], 
suggesting complex and opposing roles of neutrophils in a tumor setting. Such 
observations continue to highlight the importance of identifying factors that may play 
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essential roles in neutrophil activation and function. In conclusion, our data suggests 
that HDAC11 appears to have a dual function in neutrophils biology; 1) HDAC11 is 
increased as neutrophils differentiate and mature, and 2) decrease in HDAC11 
correlates with functional activity of neutrophils. Our studies reveal that HDAC11 plays a 
role in neutrophil chemokine and cytokine biology and function. Given the multifaceted 
function of neutrophils, the key findings described here will potentially lead to targeted 
epigenetic therapies to influence diseases involving neutrophils. 
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Chapter 3: HDAC11 Function as a Transcriptional Regulator in Immature Myeloid 
Cells (IMCs) to Myeloid-derived Suppressor Cells (MDSCs) transition 
 
3.1 List of Abbreviation 
APCs: Antigen Presenting Cells  
ATCC: American Type Culture Collection  
C/EBPβ: CCAAT-enhancer-binding protein beta 
ChIP: Chromatin Immunoprecipitation  
DCs: Dendritic Cells  
FBS: Fetal Bovine Serum  
HDACs: Histone Deacetylases  
HDAC11: Histone Deacetylase 11  
HDAC11KO: HDAC11 Knock-out  
IL-1b: Interleukin-1 beta  
IL-6: Interleukin-6  
IMCs: Immature Myeloid Cells 
 68 
iNOS: Inducible Nitric Oxide Synthetase 
IP: Intraperitoneally  
IV: Intravenous 
LPS: Lipopolysaccharides  
MDSCs: Myeloid-derived Suppressor Cells 
mRNA: Messenger RNA  
NO: Nitric Oxide 
PBS: Phosphate Buffered Saline  
qRT-PCR: Quantitative Reverse Transcriptase-polymerase Chain Reaction  
WT: Wild-type 
 
3.2 Abstract 
Myeloid-derived suppressor cells constitute a heterogeneous population of 
immature myeloid cells derived from bone marrow and possess the ability to negatively 
regulate both innate and adaptive immunity in the tumor microenvironment in large 
scale solid tumor settings.  Previous work in our lab had demonstrated that MDSCs 
lacking histone deacetylase 11 (HDAC11), a newly identified member of the HDAC 
family, revealed an increase in suppressive ability against CD8+ T cell cytotoxicity. 
However, the mechanisms of HDAC11 that contribute to the suppressive function of 
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MDSCs remain unclear. In this study, we have evaluated a number of factors implicated 
in MDSCs-mediated immune suppression, such as arginase activity, NO and ROS 
production. Our data suggest that arginase activity and NO production is significantly 
higher in HDAC11 knockout MDSCs when compared with C57BL/6 wild type control. 
Acquisition of this elevated suppressive function in HDAC11 KO MDSCs is possibly 
mediated through an up-regulation of transcription factor CCAAT-enhancer-binding 
protein beta (C/EBPβ). Also, we observed a markedly higher expression of C/EBPβ in 
CD11b+ Gr1+ from HDAC11 KO animals under tumor challenge as well as at steady 
state. Additionally, our data showed that HDAC11 was recruited to the promoter region 
of C/EBPβ in wild-type MDSCs, suggesting that HDAC11 serves as a negative regulator 
of C/EBPβ.    
 
3.3 Introduction 
In both cancer patients and tumor bearing animals, the presence and 
progression of tumors often contribute to the development of immune dysfunction which 
introduces challenges and negative feedbacks to the development of 
immunotherapeutic strategies. Multiple cell types have been identified to regulate tumor 
mediated immune evasion and immunosuppression, including regulatory T cells [180], 
tumor associated macrophages and MDSCs . As one of the major cell populations that 
infiltrated into the tumor site, MDSCs are believed to involve largely with the 
unresponsiveness of antigen specific CD8+ T cells in the tumor microenvironment [181]. 
Recently, two major subsets of MDSCs have been identified based on their morphology 
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and surface markers expression: monocytic MDSC (M-MDSC) and granulocytic MDSC 
(G-MDSC, also called polymorphonuclear PMN-MDSC) [35, 36]. In mice, MDSCs are 
recognized as cells that express Gr-1+CD11b+ phenotype and further M-MDSCs are 
characterized as CD11b+Ly6G-Ly6Chigh while G-MDSCs are characterized as 
CD11b+Ly6G+Ly6Clow [36-38]. However, in cancer patients, the phenotype of human 
MDSCs remains unclear. So far, human M-MDSCs are defined as 
CD11b+CD14+CD33+HLA-DR-/lowCo-receptor-/low and while G-MDSCs as 
CD11b+CD15+CD33+Lin-HLA-DR-/low expressing cells [8, 39]. 
MDSCs display a wide range of mechanisms to restrain the function of antigen 
specific and non-specific T lymphocytes in vitro. They express high levels of 
immunosuppressive enzyme arginase and NO/nitric oxide synthetase (iNOS), as well as 
reactive oxygen species (ROS) [38, 42, 162, 182, 183]. A recent study has revealed 
several transcription factors that are activated by GM-CSF, IL-6 and other cytokines or 
growth factors, which regulate MDSC differentiation and function. Marigo and 
colleagues had recently provided new insight demonstrating that the transcription factor 
CCAAT-enhancer-binding protein beta (C/EBPβ) plays a crucial role in the 
differentiation and immunosuppressive function of BM-derived and tumor-induced 
MDSCs [31]. Of note, mice lacking C/EBPβ in the bone marrow compartment lose the 
ability to differentiate from IMCs into pathologically active MDSCs, possibly through a 
reduction of arginase 1 and Nos2 proteins [31].  
A growing knowledge of epigenetic modification has been shown to regulate 
hematopoiesis under different pathological conditions such as infection and cancer 
[146, 184]. HDAC11, the newest member of the HDAC family, was first identified in 
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2002 as a 39 kDa enzyme and the only class IV HDAC [79]. Northern analyses and 
real-time PCR data from Gao and colleagues had confirmed a high expression level of 
HDAC11 in brain, testis, some types of B-cell lymphomas and leukemias in humans 
respectively [79]. The functional role of HDAC11 played in the immune system was 
unclear until Villagra et al first uncovered that this HDAC serves as a negative regulator 
of IL-10 expression in macrophages [80]. Neutrophils lacking HDAC11 displayed a 
functionally more active phenotype as well as enhanced migratory and phagocytic 
capacity [185]. Moreover, data published by Woods and colleagues showed that down-
regulation of HDAC11 was required for T cell activation. This has further been 
confirmed with a hyper-proliferative and responsive phenotype of HDAC11 Knockout T 
cells [82]. These studies hinted at a positive feedback of innate and adaptive immune 
response in a system devoid of functional HDAC11 protein. Although adoptive transfer 
of HDAC11KO T cells had significantly delayed tumor progression in a murine 
syngeneic lymphoma model [82], inoculation of murine thymoma or pancreatic cancer 
cells to HDAC11 total KO mice demonstrated enhanced tumor growth kinetics when 
compared with wild-type [155], hinting a hidden mechanistic role of HDAC11 in the 
immunosuppressive compartments in cancer. Notably, Sahakian had uncovered that in 
responding to antigen-specific OVA peptide, IFN-γ production from OT-1 CD8+ T cells 
was significantly decreased when co-cultured with HDAC11KO MDSCs when compared 
with Wild-type MDSCs [155], indicating that HDAC11KO MDSCs are functionally more 
suppressive. However, the mechanism of HDAC11 in MDSCs expansion and function 
remains to be elucidated. Here for the first time, we demonstrate a previously unknown 
mechanistic role of HDAC11 as a transcriptional regulator of C/EBPβ in MDSCs. 
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Indeed, in the absence of this epigenetic checkpoint of C/EBPβ gene expression, the 
fully suppressive potential of MDSCs was fully unleashed.  A better understanding of 
this novel role of HDAC11 in myeloid biology will ultimately lead to targeted epigenetic 
therapies to manipulate the suppressive abilities of these immunoregulatory cells. 
 
3.4 Material and methods 
3.4.1 Mice and cell line: C57BL/6 and B6-Lyz2tm1(cre)lfoIJ mice were purchased 
from The Jackson Laboratory.  HDAC11 knockout mice were supplied by Merck 
Research Laboratory and obtained from Dr. Seto’s laboratory at The George 
Washington University Cancer Center. The HDAC11KO mice were on a C57BL/6 
background and were generated by targeted deletion of floxed exon 3 of the HDAC11 
gene. HDAC11 myeloid cell conditional knockout (HDAC11 KO LyZ-Cre) mice were 
generated by breeding B6-Lyz2tm1(cre)lfoIJ  transgenic mice with HDAC11 flox/flox mice 
for greater than 10 generations. The third exon of HDAC11 gene, flanked by LoxP sites, 
is excised only in myeloid cells expressing the lysozyme 2 gene (Lyz2) which drive the 
expression of cre-recombinase. All mice were housed in pathogen-free conditions in the 
same designated room of the animal facility at H. Lee Moffitt cancer center and The 
George Washington University. All animal studies were performed according to the 
guideline of approved protocols by the Institutional Animal Care and Use Committee 
(IACUC) at the University of South Florida and The George Washington University. 
EL-4 murine thymoma was purchased from ATCC and cultured and maintained 
in Dulbecco’s modified Eagle’s medium (DMEM, Corning) supplemented with 4 mM L-
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glutamine, 4500 mg/L glucose, 1mM sodium pyruvate, 1500 mg/L sodium bicarbonate, 
10% horse serum (ATCC), 100 U/mL penicillin and 100 µg/mL streptomycin. Cell line 
was grown under humidified conditions at 5% CO2 and 37ºC. Cells were frozen at early 
passages (less than 6) in 95% culture medium + 5% DMSO and were used within 30 
days of recovering. 
3.4.2 Genotyping: To identify the genotypes of HDAC11KO, HDAC11 flox/flox 
and Lyz-CreHDAC11 conditional KO mice, total genome DNA was isolated and a 
polymerase chain reaction (PCR) experiment was performed with specific forward and 
reverse primers.  
Briefly, approximately 0.5 cm of tail snips was obtained from each mouse and 
then digested overnight in a lysis buffer containing 10 mM Tris-HCl (PH 8.0), 50 mM 
NaCl, 25 mM EDTA, 0.5% SDS and 10 mg/mL proteinase K at 55 ºC. 6M NaCl was 
added to each sample followed by 15 seconds of vortexing then 30 minutes of 
centrifugation at 13,000 g at room temperature. The supernatant was transferred to a 
new conical tube containing 100% ethanol and DNA precipitated by inverting the tube. 
After spinning down at 13,000 g for 10 minutes, DNA pellets were washed once with 
75% ethanol and then resuspended in Tris-EDTA buffer. DNA concentration and quality 
was determined. 
Primer sequences used for each strain are as follows: HDAC11KO Forward 
(TGCTGCCTGTGAGCCACTGC), Reverse (CCTTGGAATAGCATCTCAGG). HDAC11-
flox Forward (TGCTGCCTGTGAGCCACTGC), Reverse 
(AGAATGGCTGTCTCCCTAAG). Lyz-Cre set 1) WT (TTACAGTCGGCCAGGCTGAC), 
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Common (CTTGGGCTGCCAGAATTTCTC). LyZ-Cre set 2) Mutant 
(CCCAGAAATGCCAGATTACG), Common (CTTGGGCTGCCAGAATTTCTC). For 
each 25 µL PCR reaction, we used 0.5 µM of forward or reverse primer, 2.6 mM MgCl2, 
0.26 mM dNTPs, 0.75U taq polymerase and 50 ng of DNA was used and product size 
was resolved on a 1.5% acrylamide gel containing SYBR safe DNA Gel Stain 
(Invitrogen). 
3.4.3 In Vivo tumor model: For in vivo tumor studies, 0.25×106 EL-4 cells were 
injected subcutaneously into the right flank of female mice that were 8 weeks old. 
Tumor volume was measured starting around Day 8 after injection or at the time when 
tumors were palpable. 
3.4.4 Splenic and tumor infiltrated MDSCs isolation: Mouse spleens or 
tumors were harvested under sterile conditions on Day 21 after subcutaneous injection. 
Total splenocytes were obtained by mashing mouse spleens through a 70 µm sterile 
cell strainer (Fisher Scientific). Mouse tumor tissue was cut into small pieces followed 
by incubation with tumor dissociation solution (RPMI-1640 supplemented with 10% 
FBS, 0.25 mg/mL Collagenase D and 60 U/mL DNase I) for 30 minutes at 37 ºC. The 
disassociated tumor cells were collected by straining through a 70 µm sterile cell 
strainer. Red blood cells from spleen and tumor cells were lysed by incubating with ACK 
lysis buffer (Gibco) for 3 minutes at room temperature. Cells were washed twice with 
PBS subsequently. MDSCs were further purified by magnetic bead isolation. Briefly, 
cells obtained from spleens or tumors were incubated with biotinylated anti-Gr-1 
antibody (Invitrogen) followed by streptavidin microbeads (Miltenyi) for 15 minutes each 
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on ice.  Gr-1+ MDSCs were isolated on LD columns (Miltenyi) according to the 
manufacturer’s instruction. 
3.4.5 BM-derived MDSCs generation: Mouse bone marrow aspirate was 
removed from the tibias and femurs by flushing with ice-cold PBS and RBCs were 
removed using ACK lysis buffer. To obtain bone marrow derived MDSCs, 5×106 bone 
marrow cells were plated into 100 mm diameter tissue culture dishes in 10 mL RPMI-
1640 medium supplemented with 10% FBS, 100 U/mL penicillin, 100 µg/mL 
streptomycin, 10 mM HEPES (Corning), 50 uM 2-mercaptoethanol (gibco), 40 ng/mL 
mouse recombinant GM-CSF (Peprotech Inc) and 40 ng/mL mouse recombinant G-CSF 
(Peprotech Inc). Cells were maintained in a humidified atmosphere with 5% CO2 at 37 
ºC for 4 days. Fresh medium was replaced from cultured cells at Day 3 [31]. Gr-1+ 
MDSCs were purified by using magnetic bead isolation for each day as previously 
described. 
3.4.6 Arginase activity assay: To determine arginase activity, an arginase 
activity assay kit was used according to the manufacturer’s instructions (Sigma-Aldrich). 
Briefly, 1×106 freshly isolated MDSCs were lysed in 100 µL lysis buffer containing 10 
mM Tris-HCl  (pH 7.4), 0.4% (w/v) Triton X-100 (Fisher), 1 µM pepstatin (Sigma-Aldrich) 
A and 1 µM leupeptin (Sigma-Aldrich) for 10 minutes on ice. Cell lysate was collected by 
centrifugation at 13,000 g for 10 minutes at 4 ºC. 40 µL of cell lysate was added to each 
of two wells of a 96 well plate, one each serving for reaction well and blank well. 50 µL 
of 1mM urea was added to the late serving for standard. 10 µL of 5× substrate buffer (8 
µL arginase buffer + 2 µL Mn solution) was then added to each sample reaction well 
and the plate was incubated for 120 minutes at 37 ºC. To stop the arginase reaction, 
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200 µL of urea reagent (100 µL reagent A + 100 µL reagent B) was added to each well 
and 10 µL of 5× substrate buffer was added to sample blank wells. The plate was 
incubated for 45 minutes at room temperature and urea concentration was defined by 
measuring the absorbance at 430 nM using a microplate reader (Bio-Rad). One unit of 
arginase activity is defined as the amount of enzyme that catalyzes the formation of 1 
µmole of L-arginine to ornithine and urea per minute. 
3.4.7 NO production assay: To detect nitrite production, 0.5 × 106 freshly 
isolated MDSCs were cultured in a 96 well plate with 150 µL RPMI-1640 medium 
supplemented with 10% FBS and 10 ng/mL mouse recombinant GM-CSF for 24 hours 
in the presence or absence of 100 ng/mL mouse recombinant IFN-γ. 100 µL of culture 
supernatant were mixed with equal volume of Greiss reagent containing 1% (100 mg) 
sulfanilamide (Sigma-Aldrich), 0.1% (10 mg) N-(1-naphthyl)ethylenediamine (Sigma-
Aldrich) and 5% (0.5 mL) H3P04 (Fisher). After incubation for 10 minutes at room 
temperature, the absorbance was measured at 550 nm using a microplate reader. 
Nitrite concentration was measured by comparing the absorbance values for the 
samples to a standard curve generated by 8 serial dilutions of 0.25 mM sodium nitrite 
(Sigma-Aldrich). 
3.4.8 ROS production: Oxidation-sensitive dye DCFDA (Invitrogen) was used to 
measure reactive oxygen species production by MDSCs. 2 to 3 ×106 freshly isolated 
BM-derived MDSCs, splenocytes or MDSC-infiltrated tumor tissue digestions collected 
from tumor bearing mice were labeled with flow antibodies against surface markers as 
following: CD11b (M1/70, BD Biosciences), Ly6G (1A8, BD Biosciences) and Ly6C (AL-
21, BD Biosciences) for 20 minutes at 4ºC. Cells were then incubated in 500 µL serum 
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free RPMI-1640 medium with 3 µM DCFDA for 30 minutes in dark at 37ºC, in the 
presence or absence of 300 nM PMA (Sigma-Aldrich). The cells were analyzed using 
flow cytometry.  
3.4.9 Quantitative Real-time PCR (qRT-PCR):  Total messenger RNA was 
extracted using Trizol (Invitrogen) according to manufacturer’s instruction. cDNA was 
synthesized from 1 µg of mRNA for each sample by using iScript cDNA synthesis kit 
(Bio-Rad). To detect gene expression, qRT-PCR was performed using a SYBR Green 
two-step system. Primers targeting specific genes were designed or purchased as 
follows: Murine C/EBPα Forward (CCCACTCAGCTTACAACAGG), Murine C/EBPα 
Reverse (GCTGGCGACATACAGTACAC). Murine C/EBPβ Forward 
(ACACGTGTAACTGTCAGCCG), Murine C/EBPβ Reverse 
(GCTCGAAACGGAAAAGGTTC). Murine HDAC11 Forward 
(AGAGAAGCTGCTGTCCGATG), Murine HDAC11 Reverse 
(AGGACCACTTCAGCTCGTTG). Murine 18s rRNA (QT 02448075, QuantiTech Primer 
Assay, Qiagen).  
3.4.10 Flow cytometry analysis and cell sorting: For flow cytometric analysis, 
cells were stained with fluorochrome-labeled monoclonal antibodies (mAbs; anti-CD11b, 
-Ly6G, -Ly6G, BD Biosciences) for 20 minutes at 4ºC and washed for 2 times with 
FACS buffer. The vitality dye 4', 6-diamidino-2-phenylindole (DAPI, 50 ng/mL, Sigma) 
was added to cells before analysis.  Data was acquired on FACSCelesta flow cytometer 
(BD Biosciences), at least 10,000 events, of the smallest population of interest, 
subsequently analyzed using FlowJo software 10.2.  
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3.4.11 Western blotting analysis: Approximately 5 to 10 ×106 MDSCs were 
lysed in RIPA buffer containing 50 mM Tris-HCl (pH. 8.0), 150 mM NaCl, 0.5% Sodium 
Deoxycholate, 0.1% SDS, 1% Triton X-100 with freshly added protease inhibitor 
(Sigma-Aldrich), phosphatase inhibitor (Santa Cruz Biotechnology). The cell lysates 
were left on ice for 30 minutes followed by 2 cycles of sonication (8 min 30s on/30s off 
for each cycle. The lysates were then mixed with 2× gel loading buffer and boiled for 10 
minutes. Samples were then resolved on 4 to 10% SDS-PAGE gels (Bio-Rad) and 
transferred to nitrocellulose membranes. Membranes were blocked with buffer 
containing 5% milk and 0.05% Tween-20 (Sigma-Aldrich) and probed with appropriate 
primary antibodies overnight at 4ºC. Membranes were then washed three times with 
wash buffer and incubated with secondary antibody for one hour at room temperature. 
Bands were visualized by chemiluminescence detection on Azure Biosystem. To 
confirm equal loading, anti-GAPDH (Sigma Aldrich) was used for each experiment. Anti-
C/EBPβ, anti-Arginase and anti-iNOS antibodies were purchased from abcam. 
 
3.4.12 Adoptive Cell Therapy: In this model, female C57BL/6 and HDAC11KO 
mice (7 to 8 weeks old) were injected with 0.25×106 EL4 cells subcutaneously into 
shaved right flanks on Day 0. A mixture of MDSCs (5×106/mouse) and CD3+ T cells 
(5×106/mouse) from was intravenously injected to the animals on Day 0 and Day 7 upon 
EL4 tumor inoculation, as described previously [186]. Briefly, on day of adoptive 
transfer, spleens were harvested from C57BL/6 and HDAC11KO EL4 bearing mice. WT 
or HDAC11KO MDSCs were labeled with biotinylated anti-Gr-1 antibody and 
streptavidin magnetic beads and positively selected on a LD column. Meanwhile, lymph 
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nodes and spleens from naïve C57BL/6 and HDAC11KO mice were harvested and 
single cell suspensions was obtained after being lysed for red blood cells. CD3+T cells 
were purified using a negative selection kit (EasySep, STEMCELL technology). Both 
MDSCs and T cells were washed twice with ice cold PBS and re-suspended in HBSS at 
a concentration of 5×106 cells/150 µL for I.V. injection. 
3.4.13 Chromatin Immunoprecipitation (ChIP): Mouse MDSCs (20×106) were 
cross-linked with 1% formaldehyde (Sigma-Aldrich) for 10 minutes at room temperature. 
The cross-linking was then stopped with 0.125 M glycine for 10 minutes at room 
temperature. The cells were washed twice with PBS and proceed with sample 
preparation. The cell pellet was lysed by 1 mL of lyse buffer (50 mM HEPES pH 7.8, 3 
mM MgCl2, 20 mM KCl, 0.25% Triton X-100, 0.5% NP-40) on ice for 10 minutes. The 
cell lysate was then transferred to a “Dounce Homogenizer” and 20 strokes were 
applied using the loose pestle A. The cell pellet was washed once with 1 mL wash 
buffer (10 mM Tris-HCl pH 8.0, 1 mM EDTA, 200 mM NaCl) and resuspended in 300 µL 
sonication buffer (50 mM HEPES pH 7.8, 140 mM NaCl, 1 mM EDTA, 0.5% SDS, 1% 
Triton X-100). 8 sonication cycles (8 minutes of 30s on/off) were applied to the samples 
followed by centrifugation for 10 minutes at 4ºC. The lysate was diluted at 1:10 with 
dilution buffer I (50 mM HEPES pH 7.8, 140 mM NaCl, 1mM EDTA, 1% Triton X-100), 
pre-cleared using Protein A Agarose beads (Millipore), and incubated with rabbit anti-
HDAC-11 antibody cocktail (BioVision and Sigma-Aldrich) on a rotator at 4°C overnight. 
Biotin-conjugated normal rabbit IgG-B (Santa Cruz Biotechnology) was added at the 
same amount of rabbit anti-HDAC-11 antibody cocktail in parallel of each sample and 
incubated on a rotator at 4°C overnight. 50 µL protein A Agarose beads was then 
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applied to each sample and incubated at 4°C for 4 hours. The beads were then washed 
twice each with dilution buffer I, dilution buffer II (50 mM HEPES pH 7.8, 500 mM NaCl, 
1 mM EDTA, 1% Triton X-100), LiCL buffer (20 mM Tris-HCl pH 8.0, 250 mM LiCl, 1 
mM EDTA, 0.5% Triton X-100), and TE buffer (10 mM Tris-HCl pH 8.0, 1 mM EDTA). 
Afterwards, beads were eluted in 100 µl elution buffer (50 mM Tris-HCl pH 8.0, 1 mM 
EDTA, 1% SDS) and incubated at 65°C for 15 minutes and the immunocomplexes were 
collected in the soluble fraction. NaCl was added to a final concentration of 200 mM and 
the crosslinking was reverted by incubating at 65°C for overnight. RNAse A (Qiagen) 
was added to 20 µg/mL to each sample and incubated at 37°C for 30 minutes. 
Proteinase K (Thermo Scientific) was then added at 100 µg/mL and incubated at 42°C 
for 2 hours. DNA was purified by using QIAquick PCR Purification Kit (Qiagen) and 
purified DNA was eluted in 100 µL TE buffer for analysis by qRT-PCR. 4 µL of DNA was 
used for each qRT-PCR reaction. The following PCR primers were used: C/EBPβ 
Forward (ATGCACACAGGCAAGTTTCA), C/EBPβ Reverse 
(TCTCTCAGGCCTCAGTTTCC). 
3.4.14 Statistics: Statistical analyses were performed using student’s t test. Data 
expressed as the mean ± SD. Probability values of p ≤ 0.05 were considered significant.   
 
3.5 Results 
3.5.1 C/EBPβ is necessary for bone marrow-derived and tumor-induced 
MDSCs. 
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Previously in our group, we have demonstrated that when compared with naive 
myeloid cells, HDAC11 expression was significantly reduced in the myeloid-derived 
suppressor cells in response to tumor challenge. Without HDAC11, MDSCs are 
functionally more suppressive by implicating antigen-specific CD8+ T cell 
unresponsiveness in vitro [155]. However, the mechanism underlying this functional 
characteristic remains uninvestigated. C/EBP transcription factor family is largely 
involved during myelopoiesis. C/EBPα is a "master regulator" of granulopoiesis at 
steady-state, whereas C/EBPβ is required for emergency granulopoiesis in response to 
cytokines and infection [187]. It wasn't until 2010, Marigo and colleagues had first 
uncovered the crucial role of C/EBPβ in regulating the immunosuppressive activity of 
MDSCs in tumor bearing host. Complete deletion of C/EBPβ resulted in full abrogation 
of MDSCs on antigen specific CD8+ T cells, possibly through reduction of expression 
and reduced enzymatic activity of arginase 1 and nitric oxide synthase 2, two enzymes 
that have previously been described as major contributors to the inhibitory ability of 
MDSCs [31, 182].  
To determine whether or not C/EBPβ is involved with the elevated suppressive 
activity of HDAC11KO MDSCs, we assessed the gene expression profile of C/EBPβ in 
WT or HDAC11KO MDSCs.  We isolated CD11b+Ly6G+Ly6Clow and CD11b+Ly6G-
Ly6Chigh cells from spleens of naive and tumor-bearing C57BL/6 WT animals (Figure 
3.1A). C/EBPβ mRNA is barely detectable in immature myeloid cells from naive mice. 
Interestingly, both CD11b+Ly6G+Ly6Clow granulocytic-MDSCs and CD11b+Ly6G-
Ly6Chigh monocytic-MDSCs from tumor bearers showed an elevated C/EBPβ mRNA 
expression compared with IMCs sharing the same surface phenotype from naive mice,  
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Figure 3.1 C/EBPβ expression is up-regulated in MDSCs with HDAC11 deletion. (A) In 
Naïve and EL4 tumor bearing C57BL/5 mice, splenic monocytes (Ly6G+Ly6Chigh cells in 
naïve mice) and monocytic MDSCs (Ly6G+Ly6Chigh cells in tumor bearing mice), as well 
as splenic neutrophils (Ly6G+Ly6Clow cells in naïve mice) and granulocytic MDSCs 
(Ly6G+Ly6Clow cells in tumor bearing mice) were flow sorted. C/EBPβ expression was 
further assessed by qRT-PCR.  (B) Ly6G+Ly6Clow Monocytes and Ly6G-Ly6Chigh 
neutrophils were flow sorted from the bone marrow of C57BL/6 mice and HDACKO 
mice. The expression of C/EBPβ profile were analyzed using qRT-PCR . (C) Gr-1+ bone 
marrow derived-myeloid cells (day o) and –MDSCs (day 4) were isolated using 
biotinylated anti-Gr-1 antibody and magnetic beads. C/EBPβ mRNA expression was 
determined by qRT-PCR. Error bars = S.E.M. Data presented for each graph is a 
representative figure from 2 individual experiments, 3 animals were used for each 
experiment. Asterisk indicates statistical significance: *P<0.05, **P<0.01, ***P<0.001. 
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suggesting that up-regulation of C/EBPβ is required during the transition of immature 
myeloid cells to MDSCs. We then flow-sorted CD11b+Ly6G+Ly6Clow and CD11b+Ly6G-
Ly6Chigh cells from WT and HDAC11KO bone marrow (Figure 3.1B). To our surprise, we 
have found out that at steady state, C/EBPβ level was significantly higher for both 
Ly6G+ and Ly6C+ IMCs lacking HDAC11. To further confirm this, we isolated BM-
derived Gr-1+ MDSCs and found up-regulated mRNA expression of C/EBPβ in 
HDAC11KO MDSCs. Given Marigo's data that C/EBPβ-deleted myeloid cells failed to 
generate functional MDSCs in vivo, we hypothesize that HDAC11KO myeloid cells are 
more suitable for MDSC generation with its abnormally high level of C/EBPβ. 
 
3.5.2 Elevated level of C/EBPβ contributes to the up-regulation of enzymes 
involved with MDSC suppression in HDAC11KO mice.  
We next evaluated whether up-regulation of C/EBPβ in HDAC11KO MDSCs 
might control suppressive immunoregulatory pathways. We isolated bone marrow cells 
from WT and HDAC11KO mice followed by a treatment with 40 ng/mL of GM-CSF and 
G-CSF for up to four days in vitro. Gr-1+ cells were then purified after 72 and 96 hours 
and immunoblottings of targets of interest were performed (Figure 3.2A). We found that 
consistent with our mRNA result, C/EBPβ protein was not detectable in Gr-1+ bone 
marrow cells at day 0 of harvest. On both day 3 and day 4, an increased C/EBPβ 
protein level was observed in HDAC11KO MDSCs along with an over-expression of 
arginase 1 (Arg1) and nitric oxide synthase 2 (Nos2). The data was further confirmed in 
splenic-MDSCs and tumor infiltrated-MDSCs isolated from WT and HDAC11 KO tumor- 
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Figure 3.2 C/EBPβ is involved with the suppressive activity of MDSCs lacking HDAC11. 
(A) Immunoblots of C/EBPβ, Arginase 1 and NOS2 in Gr-1+ MDSCs isolated from WT 
and HDAC11KO mice fresh bone marrow (indicated as day 0) and BM cells treated with 
GM-CSF and G-CSF for 72 and 96 hours (day 3 and day 4). (B) Immunoblots of 
C/EBPβ in Gr-1+ MDSCs isolated from spleens and tumors of WT or HDAC11KO mice 
bearing EL4 tumor at Day 21. LAP*, LAP and LIP indicate three isoforms of C/EBPβ 
protein.  
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bearing mice. As shown in Figure 3.2B, C/EBPβ, in the absence of HDAC11, Arg1 and 
Nos2 protein level were increased in both splenic- and tumor infiltrated- MDSCs. 
Interestingly, C/EBPβ and Nos2 displayed a stronger expression profile in MDSCs 
isolated from tumor site, where as Arg1 level seems to be similar in between these two 
sources. Earlier studies had pointed out the transcriptional regulation by C/EBPβ of 
Arg1 and Nos2 genes [188-190]. In Marigo's recent work, loss of C/EBPβ results in a 
reduction to near complete depletion of both Arg1 and Nos2 protein in MDSCs [31]. 
With these observations, we believe that the loss of HDAC11 is associated with the up-
regulation of Arg1 and Nos2 through transcription factor C/EBPβ. 
 
3.5.3 HDAC11 deletion promotes MDSCs suppressive activity through 
increased arginase activity and NO production. 
Previous studies had demonstrated that arginase activity, NO and ROS production were 
the main effectors of MDSC's suppressive function. Up-regulation of Arginase 1 activity 
results in rapid uptake of L-arginine from the tumor microenvironment which contributes 
to the loss of the CD3ζ chain and prevents T cell proliferation [48, 162, 182]. Increased 
NO synthase expression can facilitate MDSCs to produce more NO and suppress T cell 
function through down-regulated downstream pathways of IL-2 receptor [162, 191]. 
Hyperproduction of reactive oxygen species (ROS) such as hydrogen peroxide and 
peroxynitrite can induce T cell apoptosis [42]. In our earlier finding, MDSCs devoid of 
HDAC11 can prevent IFN-γ production in antigen- specific CD8+ OTI T cells in 
responding to OVA peptide. HDAC11 deficient mice displayed an enhanced tumor 
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growth pattern which indicates a more suppressive microenvironment in those tumor 
bearing animals when compared with WT.  
To further compare the suppressive functional activity of WT and HDAC11KO 
MDSCs, we performed arginase activity and NO production assays (Figure 3.3 and 
Figure 3.4). Bone marrow cells were collected from WT and HDAC11KO mice followed 
by GM-CSF and G-CSF treatment for four days. Gr-1+ cells were isolated at each day 
 
Figure 3.3 Enzymes involved in the suppressive pathways employed by BM-derived 
MDSCs with HDAC11 deletion. (A) Gr-1+ MDSCs were isolated from bone marrow and 
treated with GM-CSF and G-CSF for 24, 48, 72 and 96 hours (day 1, 2, 3 and 4). The 
enzymatic activity of Arginase was evaluated from cell lysate as previously described. 
(B) Bone marrow-derived Gr-1+ MDSCs from WT or HDAC11KO mice were also plated 
in complete RPMI-1640 medium containing GM-CSF, with or without IFN-γ for 24 hours. 
Cell supernatants were collected and assayed for NO production to determine Nos2 
activity. Error bar = S.E.M. Asterisk indicates statistical significance: *P<0.05, **P<0.01, 
***P<0.001. 
 
 87 
and arginase activity evaluated from cell lysate. Accordingly, arginase activity was 
significantly increased in HDAC11KO MDSCs on both day 3 and 4 (Figure 3.3A). After 
24 hours of IFN-γ stimulation, NO production was measured from culture medium. 
HDAC11KO MDSCs facilitated significant increase of NO than WT on day 3 and day 4 
(Figure 3.3B).  
Next we performed similar experiments in splenic- and tumor infiltrated-MDSCs 
(Figure 3.4). Interestingly, splenic-MDSCs isolated from WT or HDAC11KO tumor 
bearing mice showed a similar (arginase activity) or moderately increased (NO 
production, not significant) activity from both enzymes (Figure 3.4A and 3.4B). However, 
upon entry into the tumor site, HDAC11KO MDSCs displayed a dramatic increase in 
arginase activity and NO production, indicating abnormal activity from both enzymes in 
cells depleted of HDAC11 (Figure 3.4A and 3.4B). Cytokines such as GM-CSF, G-CSF 
and IL-6 produced by tumor are some of the main factors that promote the suppressive 
function and differentiation of MDSCs [43, 192]. Given our previous observation that 
C/EBPβ protein levels are significantly higher in tumor infiltrated-MDSCs than in splenic-
MDSCs, we believe that in response to cytokines such as GM-CSF and G-CSF, up-
regulation of C/EBPβ in HDAC11KO MDSCs facilitates their ultra suppressiveness in 
the tumor microenvironment. 
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Figure 3.4 Enzymes involved in the suppressive pathways employed by HDAC11KO 
MDSCs in vivo. (A) Gr-1+ MDSCs were isolated from spleens and tumors of C57BL/6 
WT or HDAC11KO mice bearing EL4 tumors at day 21. The enzymatic activity of 
Arginase was evaluated from cell lysate as previously described. (B) Gr-1+ MDSCs from 
WT or HDAC11KO tumor bearers were also plated in complete RPMI-1640 medium 
containing GM-CSF, with or without IFN-γ for 24 hours. Cell supernatants were collected 
and assayed for NO production to determine Nos2 activity. Tumors were collected on 
day 21 after EL4 inoculation. Cells were stimulated with or without PMA in RPMI 
medium for 30 minutes then labeled with anti-CD11b, anti-Ly6G and anti-Ly6C 
antibodies. ROS was measured in G-MDSCs (C) and M-MDSCs (D) population by 
labeling cells with DCFDA. Mean florescence intensity (MFI) is shown in each indicated 
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figure. Error bar = S.E.M. Asterisk indicates statistical significance: *P<0.05, **P<0.01, 
***P<0.001. 
 
3.5.4 HDAC11 negatively regulates C/EBPβ expression by interacting with 
the promoter region of this transcription factor. 
Given our presented data so far, we hypothesize that HDAC11 could be a 
negative regulator of C/EBPβ. The higher mRNA expression of C/EBPβ in HDAC11KO 
immature myeloid cells may indicate that those IMCs are ready to differentiate into 
functional suppressive MDSCs when recruited into the tumor microenvironment. To 
further elaborate the mechanism of how HDAC11 regulates C/EBPβ, we performed 
chromatin-immunoprecipitation analysis. Gr-1+ MDSCs isolated from C57BL/6 WT and 
HDAC11KO tumor-bearing mice were cultured in medium for 3 hours with or without 
LPS. ChIP data suggest that HDAC11 was present on the promoter region of C/EBPβ in 
WT MDSCs (Figure 3.5A), with an enrichment ratio at least 2.5 fold higher than 
HDAC11KO MDSCs (Figure 3.5B) which serves as a negative control. These data 
suggest that HDAC11 could alter the expression of C/EBPβ through chromatin 
remodeling or simply function as a transcription factor. Unlike other HDACs, there has 
been no literature reporting on HDAC11’s ability to bind to DNA directly or, coupled with 
other proteins, to directly facilitate transcription initiation or regulation. At this point we 
could not fully answer the question of how HDAC11 negatively regulates C/EBPβ. A 
more in-depth study is required to fully understand the mechanism. 
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Figure 3.5. HDAC 11 regulates C/EBPβ expression in MDSCs. MDSCs were purified 
from C57BL/6 mice and HDACKO mice for Chromatin-immunoprecipitation. ChIP 
studies showed the presence of HDAC11 protein to the promoter region of C/EBPβ in 
C57BL/6 mice MDSCs (A) but not MDSCs from HDAC11 KO mice (B). Error bars = 
S.E.M. Asterisk indicates statistical significance: *P<0.05, **P<0.01, ***P<0.001. 
 
3.5.5 Mice with HDAC11 deletion in myeloid compartment displayed 
enhanced tumor progression compared to total knockout mice.  
Our previous work demonstrated an enhanced tumor progression pattern in 
HDAC11KO tumor bearers. Woods and Woan in our lab had found out that T cells 
possessed a hyper reactive phenotype and enhanced anti-tumor efficacy in vivo [82]. In 
their study, FCmuMCL tumor bearing mice established a significant delay in tumor 
growth and reduced tumor volume when adoptively transferred with HDAC11KO T cells 
[82]. We thought the HDAC11 total knockout mouse might not serve as the best model 
to study MDSCs function in vivo. Taking that into consideration, we decided to establish 
a mouse model with a linage-specific HDAC11 knockout in the myeloid compartment 
only. In Figure 3.6, our in vivo experiment show that upon EL4 tumor challenge, mice 
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with HDAC11 myeloid-lineage conditional knockout displayed enhanced tumor growth 
when compared with HDAC11 total knockout and WT mice, possibly resulting from the 
absence of HDAC11KO T cells in the tumor microenvironment. However, tumor grew 
larger in HDAC11 total knockout mice compared with WT mice, indicating that although 
the hyperactive HDAC11KO T cells could function against tumor progression, but when 
encountered with HDAC11KO MDSCs, at least in this model, their anti-tumor capability 
were limited.  
 
 
Figure 3.6 Mice lacking HDAC11 in the myeloid compartment demonstrate a more 
enhanced tumor growth pattern than HDAC11 total knock out. 0.25×106 EL4 cells were 
subcutaneously injected to C57BL/6 mice, HDAC11KO mice and HDAC11KO Cre-LyZ 
mice (n=5 per group) for up to 19 days. Tumor volume was measured for every 3 days 
after the initiation of tumors. The tumor growth pattern was analyzed to compare 
HDAC11 total KO mice with mice lacking HDAC11 in the myeloid compartment 
(HDAC11 KO Cre-LyZ), HDAC11 KO mice with C57BL/6 WT mice and HDAC11KO 
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Cre-LyZ with C56BL/6 mice. (Error bar = S.E.M). Asterisk indicates statistical 
significance between WT and HDAC11 KO, WT and HDAC11 KO Cre-LyZ, HDAC11KO 
and HDAC11KO Cre-LyZ tumor bearing mice: *P<0.05, **P<0.01, ***P<0.001. 
 
3.5.6 HDAC11 plays a contradictory role in regulating MDSCs and T cells in 
the tumor microenvironment.   
To further investigate the contradictory role of HDAC11 plays in MDSCs and T 
cells, we performed an in vivo experiment where we adoptively transferred a single cell 
type or a mixture of MDSCs and T cells (from WT or HDAC11KO) to C57BL/6 EL4 
tumor bearers. Briefly, on day 0, 9 groups of C57BL/6 mice were inoculated with EL4 
tumor cells subcutaneously. Two adoptive transfers of MDSCs and/or T cells were given 
to indicated mice on day 0 and day 7.  In figure 3.7A, we found out that adoptive 
transfer of HDAC11KOT cells into EL4 tumor bearing mice can significantly reduce 
tumor progression than mice receiving WT T cells. Notably, tumor volume of mice 
receiving HDAC11KO MDSCs alone is significantly larger than mice that received WT 
MDSCs, which is expected given the enhanced suppressive phenotype of those cells 
(Figure 3.7B). Additional transfer of HDAC11KO T cells significantly reduced both 
MDSC-promoted tumor growth in mice receiving WT MDSCs or HDAC11KO MDSCs 
(Figure 3.7C, 3.7D). However, the anti-tumor effect by HDAC11KO T cells was affected 
when they encounter HDAC11KO MDSCs in the tumor microenvironment (Figure 3.7E, 
3.7F).  
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Figure 3.7 The antitumor efficacy by adoptive transfer of HDAC11KO T cells can be 
diminished by MDSCs lacking HDAC11. 0.25 × 106 EL4 cells were subcutaneously 
injected to 9 groups of C57BL/6 mice on day 0 (n=5 per group). On day 0 and day 7, 
mice were given WT MDSCs, H11KO MDSCs, WT T cells, H11KO T cells alone or a 
mixture of WT or 11KO MDSCs with naive WT or 11KO T cells intravenously. For each 
mouse receiving adoptive transfer, 5 × 106 MDSCs or T cells were used. One group of 
mice receiving only EL4 tumor cells served as No i.v control.  Tumor volume was 
measured for every 2 days after the initiation of tumors. The tumor growth pattern was 
analyzed in comparison with (A) C57BL/6 tumor-bearing mice with adoptive transfer of 
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C57BL/6 WT T cells alone, HDAC11KO T cell alone and No i.v control, (B) C57BL/6 
tumor-bearing mice with adoptive transfer of WT MDSCs alone, HDAC11KO MDSCs 
alone and No i.v control, (C) C57BL/6 tumor-bearing mice with adoptive transfer of WT 
MDSCs alone, WT MDSCs + WT T cells, WT MDSCs + HDAC11 KO T cells and No i.v 
control, (D) C57BL/6 tumor-bearing mice with adoptive transfer of HDAC11KO MDSCs 
alone, HDAC11KO MDSCs + WT T cells, HDAC11KO MDSCs + HDAC11KO T cells 
and No i.v control. (E) C57BL/6 tumor-bearing mice with adoptive transfer of WT 
MDSCs + WT T cells, HDAC11KO MDSCs + WT T cells, WT T cells alone. (F) C57BL/6 
tumor-bearing mice with adoptive transfer of WT MDSCs + HDAC11KO T cells, 
HDAC11KO MDSCs + HDAC11KO T cells, HDAC11KO T cells alone. (Error bar = 
S.E.M). Asterisk indicates statistical significance: *P<0.05, **P<0.01, ***P<0.001. 
 
3.6 Discussion 
Myeloid-derived suppressor cells represent a heterogeneous population of 
immature myeloid cells that are recruited to the tumor microenvironment where they 
differentiate into immunosuppressive cells. As one of the main mechanisms that 
facilitate the immune evasion of cancer, MDSCs have garnered a great deal of interest 
from scientific investigators and were believed to be a potent target for therapeutic 
approaches against cancer. Here we showed for the first time that among all the 
HDACs known, through negative regulation of C/EBPβ, HDAC11, the newest member 
of this family of enzymes, promotes the suppressive function of MDSCs in mouse 
model.  
C/EBPβ had been recently demonstrated to control emergency granulopoiesis 
induced by cytokines such as GM-CSF or infection [187]. It is the discovery of C/EBPβ 
deletion could mostly eliminate MDSC suppressive activity until investigators first 
associate this molecule with MDSC development and biological function [31]. Previously 
we have found out that in the absence of HDAC11, MDSCs display an enhanced 
suppressive phenotype against antigen-specific CD8+ T cell function and promote tumor 
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progression [155]. However, little is known regarding the C/EBPβ expression profile in 
MDSCs devoid of HDAC11. In our study, we observed an increased C/EBPβ level in 
HDAC11KO BM-derived MDSCs compared with WT. C/EBPβ is generally not 
detectable in myeloid cells at steady state. To our surprise however, we detected a 
markedly higher expression of C/EBP-β mRNA in both CD11b+Ly6G+Ly6Clow and 
CD11b+Ly6G-Ly6Chigh compartments at steady state in HDAC11KO vs WT control, 
indicating a possibility of HDAC11KO myeloid cells being primed and ready to 
differentiate into functional MDSCs (Figure 3.1). Additionally, in the absence of 
HDAC11, we have detected an increased protein level of C/EBPβ in in vitro cultured 
BM-derived MDSCs, as well as splenic and tumor-infiltrated MDSCs from our in vivo 
tumor model when compared with WT (Figure 3.2). Moreover, ChIP analysis results 
suggest that HDAC11 was recruited to the promoter region of C/EBPβ, indicating a 
direct or indirect transcriptional machinery involved with HDAC11 (Figure 3.5). Along 
with that, two enzymes known to be associated with C/EBPβ, arginase 1 and nitric oxide 
synthase 2 showed increased protein level in HDAC11KO MDSCs compare with WT 
(Figure 3.2). In MDSCs, arginase activity, NO and ROS production are the main 
effectors to suppress T cell function. We next assessed enzymatic activity analysis for 
those factors. Our data suggest that in the absence of HDAC11, in vitro GM-CSF and 
G-CSF induced MDSCs displayed a higher arginase activity and NO production (Figure 
3.3). Similarly, tumor-infiltrated HDAC11KO MDSCs had a dramatic increase of both 
Arg1 activity and NO, but not ROS production (Figure 3.4). However, both arginase 
activity and NO level were at a similar level in the splenic-MDSCs from tumor bearing 
mice. Both Arg1 and iNOS use L-arginine as a substrate and the uptake of L-arginine 
 96 
from the tumor microenvironment can suppress T cell function through multiple 
pathways [48, 193, 194]. Taken together, our data suggest that through arginine 
metabolism regulated by C/EBPβ-induced enzyme Arg1 and Nos2, HDAC11KO MDSCs 
function more suppressive in the tumor microenvironment.  
In addition to having increased suppressive phenotypes in HDAC11KO MDSCs, 
studies have shown that T cells lacking HDAC11 had enhanced effector function 
against tumor [82]. Our observation in HDAC11 myeloid-lineage conditional knockout 
provides evidence to support this finding. In solid tumor, the microenvironment consist 
of a heterogeneous population of tumor cells, stromal cells, fibroblasts and a mixture of 
different immune cells such as T cells, MDSCs, tumor associated macrophages and 
regulatory T cells. Deletion of HDAC11 in the knockout mouse will inevitably affect all 
cell types and will bring an uncertainty in how to interoperate our data. Using the 
HDAC11 Cre-LyZ conditional knockout model allow us to investigate the suppressive 
function of MDSCs without interference from HDAC11KO T cells. When challenged with 
tumor, the HDAC11 Cre-LyZ mice indeed showed a dramatic increase in tumor 
progression compared with total knockout mice (Figure 3.6). This finding provides 
evidence to allow us to further investigate the contradictory role HDAC11 played in the 
tumor microenvironment.  
In our in vivo study, tumor progression in C57BL/6 tumor bearing mice receiving 
HDAC11KO T cells was significantly reduced than mice receiving WT T cells, whereas 
adoptive transfer of HDAC11KO MDSCs alone could promote tumor growth (Figure 
3.7A, 3.7B). Additional transfer of HDAC11KO T cells could significantly reduce both 
MDSC-promoted tumor growth in mice receiving WT MDSCs or HDAC11KO MDSCs 
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(Figure 3.7C, 3.7D). However, the anti-tumor effect by HDAC11KO T cells was affected 
and reduced when co-existing with HDAC11KO MDSCs. When encountered with both 
HDAC11KO and WT T cells, WT MDSCs appeared to have a milder suppression 
(Figure 3.7E, 3.7F). Based on our data, we hypothesize that to gain a full anti-tumor 
effect from T cells by HDAC11 inhibition, it is necessary to eliminate MDSC function or 
infiltration.  
A growing body of evidence has demonstrated that targeting HDAC11 could be a 
potent therapeutics against in multiple cancer cell lines or across different cancer types 
[84, 87, 195]. There are a few HDAC11 inhibitors commercially available and hopefully 
more will be generated with a higher specificity. Inhibition of HDAC11 activity either as 
stand-alone or in combination with other therapies will inevitably target the host immune 
system and tumor cells simultaneously. With its potent ability to target cancer cells 
directly, the additional effect on T cell function could boost the anti-tumor capability of 
the drugs. However, this effect could be potentially jeopardized by the benefit of 
HDAC11 inhibition to MDSCs. In addition to HDAC11 inhibition blockade of MDSC 
infiltration or elimination of its function could potentially provide a better outcome as a 
new therapeutic approach. Growing interest has focused on MDSC inhibition in cancer 
patients. Targeting GM-CSF signaling or CSF-R blockade could potentially benefit 
chemotherapy and reverse resistance to immunotherapy in vitro [196, 197]. Inhibiting 
MDSC NO production through Nrf2 degradation by RTA 408, which is currently being 
evaluated in clinical trials, benefits the outcome of treatment with its anti-cancer and 
anti-inflammatory activity [198]. C/EBPβ could also serve as a potential target in 
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reducing MDSCs function as a few inhibitors are available but need to be further 
evaluated [199, 200].   
Taken together, these studies have allowed us to identify HDAC11 as a novel 
regulator of the tolerogenic and immunosuppressive microenvironment induced by 
cancer. The dual role of HDAC11 in regulating MDSCs suppressive function and T cell 
anti-tumor effect reflects the complexity of its function and sheds lights on the 
therapeutic potential of this novel molecule.  
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Chapter 4:  Conclusions and Future Directions. 
 
HDAC11 was first discovered and cloned in 2002 and was characterized as a 
small protein with 39 kDa molecule weight and expressed largely different among 
different tissues [79]. It shared limited similarity with other HDACs in its family, and was 
thus given its own class as Class IV HDACs. Unlike other HDACs in its family, little is 
known of HDAC11's function among the scientific community. HDAC11 has the 
potential to regulate DNA replication through manipulation of chromatin structures and 
alter chromatin accessibility to transcription in a few genes such as cdt1, cdc25A and 
oligodendrocyte specific genes MBP and PLP genes [91, 201, 202]. Recently, HDAC11 
depletion is believed to cause cancer cell death and inhibit the metabolic activities in a 
few cancer cell lines, including colon, prostate, breast and ovarian lines by using a 
catalytically impaired variant of HDAC11 [84]. Other HDACs have been shown to 
demonstrate an effect on both cancer cells and the host immune system. However, the 
regulatory role of HDAC11 on the immune system is still undergoing investigation. In 
order to assess the capability of HDAC11 as a potential therapeutic, a better 
understanding of its function is urgently needed.  
Knocking out HDAC11 in the mouse model is not lethal, at least in the C57BL/6 
background. Extensive studies in our group have illuminated a unique role of HDAC11 
in the immune system. In our observations, in other experiments performed in the 
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laboratory outside of this thesis, there is no difference in the size of major organs such 
as the brain, spleen, liver, thymus and heart from HDAC11KO mouse. In addition, 
lymph nodes appear to be slightly larger in the knockout. HDAC11KO animals also 
share relatively similar blood counts for monocytes, granulocytes, white blood cells and 
lymphocytes, whereas colony forming assay results showed a slight increase of CFU-M, 
CFU-G, CFU-GM colonies with a dramatic increase of the CFU-PreB colony (data not 
shown in this dissertation). In Chapter 2 we have reviewed the evidence that aging 
HDAC11KO mice (18 months old) demonstrated BM hypercellularity with granulocytic 
expansion and splenomegaly, possibly resulting from increased extramedullary 
hematopoiesis. Additionally, a significant decrease in the viability of neutrophils isolated 
from the HDAC11KO mice bone marrow was observed when these cells were 
stimulated with GM-CSF compared to WT control, indicating that HDAC11KO 
neutrophils have an even shorter life span in response to stimulation. So far we have 
uncovered no evidence regarding the long-term survival for HDAC11KO MDSCs.  
Using the HDAC11-eGFP transgenic mouse model, previous members in our lab 
were able to visually identify the HDAC11 gene expression profile in immune cells. Their 
data suggest that HDAC11 expresses at a higher level in the neutrophils/granulocytes, 
but remains low in the macrophages/monocytes. Activation of both CD4+ and CD8+ T 
cells required a decreased expression of HDAC11. While differentiated into MDSCs, 
HDAC11 signal was lost compared with immature myeloid cells express the same 
surface marker as MDSCs. Tumors can promote multiple mechanisms to induce 
immune dysfunction in both mouse and human. The unique expression profile of 
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HDAC11 drove researchers in our group to further investigate the role of this molecule 
in different lineage immune cells.  
Villagra demonstrated that HDAC11 regulates the chromatin accessibility for 
transcriptional regulation in the promoter region of IL-10 in macrophages [80]. Woods 
found out that deletion of HDAC11 permits a hyper active phenotype in T cells with an 
upregulation of transcription factor T-bet and Eomes [82]. Huang from the Hancock lab 
discovered an increased expression of Foxp3 and TGF-β, along with increased 
suppressive function in Foxp3+ Tregs [83]. Sahakian published work in identifying 
HDAC11KO MDSCs that possessed an enhanced ability to suppress T cell function and 
promote tumor progression [155]. This dissertation discussed the influence of HDAC11 
in neutrophil biology, as well as its role in regulating MDSC function through 
transcriptional regulation of C/EBPβ. In collaboration with Sahakian, we found out that 
neutrophils lacking HDAC11 gained migratory and phagocytic ability, with an increased 
cytokine production profile (TNF-α, IL-6 and IL-1β, data for IL-1β cytokine production is 
not listed in this dissertation).  Furthermore, the deletion of HDAC11 seems to grant 
neutrophils a more active phenotype upon infection. The continuous work carried on 
from this MDSCs study was discussed previously in chapter 3. We found out that the 
ultra suppressive phenotype of MDSCs lacking HDAC11 was possibly regulated 
through transcription factor C/EBPβ, which was proven to be associated with MDSC 
suppressive factor Arg1 and Nos2. With an increased level of Arg1 and Nos2, L-
arginine metabolism was increased in HDAC11KO MDSCs, granting those cells 
enhanced suppression.  
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Taken all together, we believe that HDAC11 plays a dual yet contradictory role in 
the host immune system. Without HDAC11's participation, under pathological conditions 
such as cancer or infection, the "immune defenders" such as neutrophils, APCs and T 
cells become functionally more active against pathogen or tumor invasion. On the 
contrary, "immune suppressors" such as MDSCs become more suppressive. 
These findings led us to believe that when targeting HDAC11 as a potential 
cancer treatment, the effect of its inhibition on both cancer cells and the immune system 
should be taken into consideration to assess its safety and effectiveness. With an 
increasing interest in the development of effective HDAC11 inhibitors, more in-depth 
investigation should be performed to gain a better understanding of the mechanisms of 
HDAC11 that affect the immune system. Data from us and other investigators suggest 
that HDAC11 regulates a broad range of genes in different cell types. HDAC11 down-
regulates cytokines such as IL-10, IL-6, TNF-α and IL-1β in matured myeloid cells, while 
repressing the expression of transcription factors such as T-bet, Eomes in T cells, 
Foxp3 in Tregs and C/EBPβ in MDSCs. Neutrophils lacking HDAC11 displayed a higher 
level of migration related genes such as MIP2 and CXCR2. Chromatin 
immunoprecipitation analysis showed the presence of HDAC11 in the promoters of 
multiple genes listed above, indicating the potential mechanism of HDAC11 in 
chromatin remodeling within those genes. Unfortunately, there is no further evidence to 
help us explain how HDAC11 regulate those genes. Data from Woods and myself did 
point out that total histone 3 in T cells and Lysine 27 on histone 3 in neutrophils (figure 
not included in this dissertation) demonstrated an increased acetylation status when 
lacking HDAC11. However, more experiments in the promoters should be performed to 
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help us understand the true mechanism. Secondly, most members in the HDAC family 
are known to function as a protein complex. Villagra had discovered that in APCs, 
HDAC11 and HDAC6 could interact in the cytosolic and nuclear compartment [78]. 
Further investigation of how these two HDACs interact as well as other proteins 
potentially associated with this regulatory complex will certainly help us unveil the 
secrets of HDAC11.  HDAC11 is predominately localized in the nucleus with a limited 
amount of protein detectable in the cytosolic compartment. It will be necessary to find 
out the mechanism of how HDAC11 is shuttling in and out of the nucleus in response to 
stimulation, which will provide a better insight into its function in immune cells. Last but 
not least, more experiments should be designed and performed to identify other 
possible pathways for MDSCs function under HDAC11 inhibition. Despite the critical 
role of C/EBPβ in regulating MDSC function, multiple pathways have been uncovered in 
the past contributing to this suppressive cell type. For instance, STAT3 was shown to 
enhance MDSC proliferation through up-regulation of cell cycle related genes such as 
Bcl-x1, cyclin D1 and survivin, as well as S100A8 and S100A9 [9, 203, 204]. A better 
understanding of the complete regulatory role of HDAC11 in MDSCs could provide 
more potential therapeutic targets in combination with HDAC11 inhibition. 
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